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Diabetes mellitus is a disease that has been rapidly increasing in prevalence 
worldwide, with more than 9% of the world’s adult population currently diagnosed, and an 
additional 4-5% thought to be living with diabetes without a diagnosis. Diabetes is caused 
by dysregulation of blood glucose homeostasis. A key regulator of blood glucose 
homeostasis is insulin secretion from -cells that reside in pancreatic islets of Langerhans. 
While much is known about the intrinsic factors that control β-cell development, less is 
known about how the interaction of β-cells with other non-pancreatic cell types controls 
development and adult function.  
Recently, our lab discovered that sympathetic nerves that innervate the pancreas 
are essential for pancreatic islet development and adult islet function (Borden et al. 2013). 
These nerves secrete the neurotransmitter norepinephrine, a potent activator of adrenergic 
signaling. During development, the mouse pancreas expresses all nine of the adrenergic G-
protein coupled receptors (GPCRs), including those most responsive to epinephrine, a 
hormone secreted from the adrenal gland that is distributed throughout the body through 
the circulatory system. This led us to hypothesize that adrenergic signaling may play a role 
in instructing endocrine pancreas development, beyond the commonly studied roles in 
acute, physiological stress responses.  
Here, we identify a sex-specific requirement for the β2-adrenergic receptor (Adrb2) 
in regulating Vegf-a production and vascularization during islet development. Loss of 
Adrb2 from islet β-cells enhances Vegf-a and insulin expression in β-cells, and results in 
hyper-vascularized islets in neonatal mice, specifically in females. Despite elevated insulin 
synthesis, adult mutant females, but not males, exhibited glucose intolerance and impaired 
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glucose-stimulated insulin secretion (GSIS), in part, due to alterations in genes involved in 
calcium regulation and exocytosis in islets. Metabolic and molecular phenotypes in adult 
Adrb2-deficient mice were fully rescued by the blockade of Vegf-a signaling and 
correction of islet hyper-vascularization during development. Consistent with a 
predominant role for Adrb2 during development, glucose homeostasis was unaffected by 
adult-specific deletion of Adrb2. Together, these findings uncover a negative regulatory 
pathway that functions in a sex-specific manner during islet formation to control long-term 
glucose metabolism by restraining excessive vascular growth. 
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Regulation of all metabolic pathways is crucial to an organism’s growth and 
survival. Disruption of even a single pathway results in a disease state. One commonly 
known metabolic disorder is diabetes mellitus, a condition in which the affected individual 
can no longer maintain physiological glucose levels. The prevalence of diabetes has been 
rapidly increasing world-wide, and it is estimated that one in eleven people are currently 
living with diabetes, but half of the diabetic population is undiagnosed at this point (IDF, 
2017). If the prevalence continues to increase at this rate, then by 2040 it is expected that 
10% of the world population will be living with diabetes (IDF, 2017). There are three main 
categories of diabetes, known as type I, type II, and gestational. While a variety of tissues 
contribute to metabolic homeostasis, the pancreatic islets of Langerhans are key 
contributors to glucose regulation. Islets only comprise approximately 2-10% of the total 
pancreatic mass but house a variety of endocrine cell types responsible for the regulated 
secretion of hormones to precisely balance blood glucose levels. The primary cell type 
within islets are β-cells, which secrete the hormone insulin. Insulin secretion is stimulated 
by high glucose conditions and signals to the rest of the body to remove glucose from the 
bloodstream. Loss of insulin production or secretion, as seen in diabetes, results in 
uncontrolled high blood sugar levels. Type I diabetes is an autoimmune disorder generally 
seen in juveniles that results in the targeted destruction of insulin producing β-cells.  The 
causes of type I diabetes are unclear, though it is thought to be a result of both genetic and 
environmental factors (IDF, 2017).  Type II diabetes, the most prevalent form of diabetes, 
is a result of ineffective insulin production or secretion from β-cells, or the development of 
insulin resistance after a time of excess insulin presence in the blood. While the causes of 
type II diabetes are also thought to be a combination of genetic and environmental factors, 
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there is a strong association with obesity (as a result of an unhealthy diet and lack of 
exercise). However, not all individuals with type II diabetes are overweight (IDF, 2017). 
Gestational diabetes only occurs during pregnancy, and often goes away within the first 
few months after giving birth. Placental hormones cause increased blood glucose levels, 
and usually enough insulin can be produced to compensate, but not always. Having 
gestational diabetes does, however, increase the risk of the mother developing type II 
diabetes later in life (IDF, 2017). Because islets are such a key contributor to glucose 
homeostasis, and their loss results in metabolic dysregulation, it is critical to understand 
how they develop.   
Untreated diabetes can cause complications that affect nearly every organ in the 
human body, causing a multitude of symptoms such as cardiovascular disease and 
blindness (Chowdhury, Shaho and Moolla 2014). Cardiovascular disease results from 
sustained elevated blood glucose levels, which can result in the thickening and narrowing 
of blood vessels due to fatty acid deposit and build-up. Blindness results from sorbitol 
buildup, which causes osmotic changes in retinal tissues leading to the degeneration of lens 
fibers (Pollreisz and Schmidt-Erfurth 2010). However, these symptoms can generally be 
controlled by medical intervention. The understanding of the defects that result in diabetes 
led to the present-day treatment of insulin injections, which can alleviate and even prevent 
the aforementioned conditions. However, this treatment is not ideal, because natural insulin 
levels oscillate every 3-9 minutes (Goodner et al, 1977; Hussain, 2014), and current insulin 
pumps are not capable of mimicking that tight regulation. Type I diabetics require insulin 
therapy for life, but type II diabetics can usually manage their disease with a combination 
of healthy diet and exercise, with the addition of insulin therapy and medications to lower 
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their blood sugar if needed. Other therapies being explored include islet transplants, in 
which islets are collected from a previously healthy donor (or multiple donors) and 
transplanted into a diabetic patient. Trials have seen preliminary successes, but there are 
still many problems with this treatment, including failure of transplanted islets to re-
vascularize, and immune rejection of the transplanted tissue. Understanding how diabetes 
develops, and therefore how pancreatic islets develop, is crucial for our understanding of 
the disease, so that in the future we can develop more effective therapies and preventative 
measures. 
 
Energy Extraction from Nutritional Fuel Substrates 
All organisms, from unicellular microbes to humans, rely on various metabolic 
pathways to grow and survive. Cells have adapted complex regulatory networks and 
specialized enzymes to extract energy from various substrates. Metabolic processes depend 
on the consumption of nutrients such as glucose, the main energy-providing molecule for 
the brain, and fatty acids, the main energy-providing molecule for the heart (Berg, 
Tymoczko and Stryer 2002). The catabolism, or breakdown, of these macromolecules 
releases high-energy molecules, such as adenosine triphosphate (ATP), nicotinamide 
adenine dinucleotide (NADH), nicotinamide adenine dinucleotide phosphate (NADPH), 
and flavin adenine dinucleotide (FADH2). These high-energy molecules are used for many 
crucial cellular processes, such as maintaining ion gradients, moving motor proteins, and 
powering anabolic reactions, or those that construct molecules from smaller units. 
Familiarization with the various metabolic pathways involved in energy generation and 
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expenditure is important for understanding the underlying mechanisms of metabolic 
diseases.  
Catabolism of Nutrients - Carbohydrate Metabolism 
The primary source of an organism’s nutritional energy is derived from 
carbohydrates, such as starch, sucrose, and lactose. These molecules provide 
approximately 4.7 kilocalories per gram (kcal/g) of energy and comprise almost 50% of all 
calories in the average human diet (Hussain, 2014). These complex carbohydrates must be 
broken down into monosaccharide constituents, such as glucose, the basic carbohydrate 
unit, before they can be absorbed by the intestine and metabolized. During a normal 24-
hour day, the average human will consume between 1800 and 2000 calories during 
intermittent cycles of feeding, such as a meal or snack, and fasting, such as six to eight 
hours of sleep (Hussain, 2014). For a metabolically healthy adult, the average eight-hour 
fasting blood glucose levels are between 70 and 100 milligrams per deciliter (mg/dL). After 
a meal, complex carbohydrates will be broken down to glucose, which will enter the blood 
stream through the intestine, causing blood glucose levels to spike. Two hours after the 
meal, blood glucose levels will fall to below 140 mg/dL (Hussain, 2014).   
Glucose – Glycolysis 
 The initial increase of blood glucose levels in the body after a meal acts as an 
extracellular signal that is sensed by pancreatic β-cells. These highly specialized endocrine 
cells respond to a glucose threshold by secreting a hormone, insulin, into the blood stream. 
Insulin is subsequently carried to target tissues (such as the liver, adipose tissue, and 
skeletal muscle), where it promotes glucose uptake into cells through a glucose transporter, 
6 
 
reducing blood glucose levels. Phosphorylation traps glucose within a cell where it is 
broken down in the cytoplasm from a six-carbon sugar into two molecules of pyruvate 
through a ten-step process known as glycolysis. The first half of glycolysis requires the 
input of two ATP molecules, while the second half of glycolysis produces two NADH, and 
four ATP molecules. This results in a net gain of two ATP, two NADH, and two pyruvate 
per glucose molecule.  
Pyruvate from glycolysis can be further metabolized in a variety of ways depending 
on the metabolic demands of the specific cell. Under aerobic conditions, pyruvate can enter 
the tricarboxylic acid (TCA) cycle, which is also known as the citric acid cycle, or the 
Kreb’s cycle. Pyruvate will be transported into the mitochondria where it will be converted 
to acetyl-CoA via pyruvate dehydrogenase (PDH), producing one NADH per pyruvate 
(two NADH per glucose molecule). Acetyl-CoA is condensed with oxaloacetate, the last 
product of the TCA cycle, to form citrate. As citrate is metabolized through the TCA cycle 
back to oxaloacetate, three NADH, one ATP, and one FADH2 are produced. This occurs 
twice per original glucose molecule, giving a total of six NADH, two ATP, and two 
FADH2.  
When blood glucose levels fall too low, pyruvate can be used by hepatocytes to 
create glucose through gluconeogenesis. During times when energy is required 
immediately, such as exercises that require fast muscle responses during anaerobic 
conditions, pyruvate will be converted to lactate, via lactate dehydrogenase, in order to 
replenish cellular NAD+ supplies. This supply is necessary for glycolysis to continue so 
that energy may be generated rapidly, without continuing through the TCA cycle and 
electron transport chain (ETC).               
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NADH and FADH2 generated from the TCA cycle move to the ETC, where 
electrons are transferred through four enzyme complexes found in the inner mitochondrial 
membrane to O2,
 the final electron acceptor. As the electrons are transferred, complexes I, 
III, and IV pump protons from the mitochondrial matrix to the intermembrane space. The 
continual pumping of these protons creates a strong proton gradient that powers the enzyme 
ATP synthase, which is located in the inner mitochondrial membrane. ATP synthase uses 
three protons from the gradient to convert adenosine diphosphate (ADP) and free 
phosphates into ATP. NADH oxidation contributes to the ETC by donating a pair of 
electrons used in complex I in the ETC. From this, one NADH will generate three ATP 
molecules. FADH2 oxidation contributes to the ETC later, at complex II, bypassing 
complex I, resulting in the production of only two ATP per FADH2 molecule. In total, one 
molecule of glucose that is metabolized through glycolysis, pyruvate oxidation, and 
subsequently the TCA cycle will produce 38 ATP, far more than glycolysis alone.  
Glucose – Pentose Phosphate Pathway 
Although the majority of glucose metabolism occurs through glycolysis, other 
metabolic pathways also utilize glucose. One example of this is the pentose phosphate 
pathway (PPP), also known as the hexose monophosphate shunt or the phosphogluconate 
pathway, which exists parallel to glycolysis. Both pathways share intermediates, and both 
are located in the cytoplasm, allowing for exchange of intermediates between pathways 
depending on the metabolic needs of the cell. The PPP shunt originates with glucose-6-
phosphate (G6P), a glycolytic intermediate. The oxidation of G6P produces the pentose 
ribulose-5-phosphate. The series of reactions, the oxidative phase of the PPP, are highly 
regulated and primarily responsible for producing NADPH, which provides reducing 
8 
 
equivalents for biosynthetic reactions (Hussain, 2014; Wamelink, Struys and Jakobs 2008). 
Some of these biosynthetic reactions take place more frequently in specialized cell types 
that have a higher need for NADPH. Adipocytes, for example, shunt up to 50% of their 
glucose through the PPP to obtain enough NADPH for fatty acid and sterol synthesis. Other 
cell types that have a high demand for NADPH include hepatocytes and erythrocytes, 
which shunt up to 10% of their glucose through the PPP. In contrast, skeletal muscle cells 
use ATP for contraction and therefore primarily metabolize glucose through glycolysis, 
and barely utilize the PPP.  
The second part of the PPP is non-oxidative and begins with the isomerization of 
ribulose-5-phosphate to ribose-5-phosphate. Ribose-5-phosphate is used by rapidly 
dividing cells, such as skin cells or tumor cells, to synthesize nucleotides and coenzymes 
(Nelson and Cox 2008). Each G6P molecule that is oxidized by G6P-dehydrogenase to 
ribulose-5-phosphate (and subsequently isomerized to ribose-5-phosphate), will produce 
two NADPH, two CO2, and two H
+. This reaction provides both NADPH for biosynthetic 
reactions and ribose-5-phosphate for nucleotide synthesis. Some cells, such as hepatocytes 
and adipocytes, which have high levels of fatty acid synthesis, have more of a need for 
NADPH, and therefore require less ribose-5-phosphate. These cells recycle the ribose-5-
phosphate produced in the oxidative phase into G6P, which then re-enters the oxidative 
phase of the PPP and leads to more NADPH production. Ribose-5-phosphate epimerase 
can also generate xylulose-5-phosphate in a reversible reaction. Transketolase, an enzyme 
unique to the PPP, can then catalyze the condensation of xylulose-5-phosphate and ribose-
5-phosphate to form glyceraldehyde-3-phosphate, a glycolytic intermediate, and 
sedoheptulose-7-phosphate. Glyceraldehyde-3-phosphate can enter glycolysis, and both of 
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these intermediates can be recycled back to G6P (Tozzi et al. 2006). In total, this pathway 
is not an ATP producing pathway, but the oxidation of each glucose molecule results in a 
gain of two NADPH. 
Glucose – 2,3 Diphosphoglycerate Pathway 
Another metabolic detour from glycolysis is the 2,3 diphosphoglycerate pathway, 
which is common in red blood cells (erythrocytes). The 2,3 diphosphoglycerate pathway 
is a single-intermediate detour around the first ATP-producing step of glycolysis, the 
conversion of 1,3-bisphosphoglycerate (1,3 BPG) to 3-phosphoglycerate (3PG). In the 2,3 
diphosphoglycerate pathway, 1,3 BPG is isomerized to 2,3 BPG by diphosphoglycerate 
isomerase. After isomerization, 2,3 BPG subsequently binds to hemoglobin and reduces its 
affinity for oxygen. While this mechanism is crucial because it allows for the release of 
oxygen to tissues, it is important that cells be economic with their use of it. Producing and 
maintaining a high concentration of 2,3 BPG is energetically expensive, because it involves 
the loss of an ATP from glycolysis. Therefore, it is unsurprising that cells carefully regulate 
the production of 2,3 BPG (Bunn 1971).  
Alternative Sugars – Sorbitol 
 Although glucose is the major carbohydrate unit responsible for energy production 
throughout the body, other sugars can also be metabolized by certain tissues. One example 
of this is sorbitol. Because the enzyme kinetics regulating the conversion of glucose to G6P 
by hexokinase (Km 0.1mM) are much more favorable than the conversion of glucose to 
sorbitol by aldose reductase (Km 150mM) (Nelson and Cox 2008, Gabbay and Tze 1972), 
sorbitol is rarely made by the human body. In a disease state, however, where an 
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individual’s blood sugar levels are elevated, aldose reductase will reduce glucose to 
sorbitol at the expense of one NADPH molecule. In tissues that also contain sorbitol 
dehydrogenase, sorbitol can be further metabolized to fructose by sorbitol dehydrogenase, 
producing one NADH. Some tissues, such as the retina, have aldose reductase but not 
sorbitol dehydrogenase. This can lead to a toxic buildup of sorbitol when an individual’s 
blood sugar levels are constantly high, thus causing retinal damage (Guo et al. 2014). In 
tissues that do have sorbitol dehydrogenase, the further metabolism of sorbitol to fructose 
can be beneficial, because fructose can be phosphorylated by hexokinase and enter 
glycolysis.  
Alternative Sugars - Fructose 
 Fructose has received much attention recently due to its possible contribution to 
obesity. However, fructose is common in a healthy diet, as it is found in most fruits and 
some vegetables (Laughlin 2014). Fructose enters the bloodstream from the gut, and the 
majority of its metabolism takes place in the liver, where it is converted in the cytoplasm 
to fructose-1-phosphate (F1P) by fructokinase. F1P is subsequently metabolized to 
dihydroxyacetone phosphate (DHAP), a glycolytic intermediate, and glyceraldehyde by 
F1P aldolase, thus bypassing the main regulator of glycolysis, phosphofructokinase-1. As 
such, a fructose-rich diet can lead to metabolic consequences, such as increased glycolysis 
without regulation (Hussain, 2014, Laughlin 2014). In cells that do not express 
fructokinase, such as adipocytes, fructose can be converted by hexokinase to fructose-6-




Alternative Sugars – Galactose 
 Galactose is another sugar that is regularly metabolized by the body. It is commonly 
found in the human diet from milk products. Galactose is converted by galactokinase to 
galactose-1-phosphate. A transferase (galactose-1-phosphate uridyl transferase) removes 
the phosphate from galactose-1-phosphate and transfers it to uridine diphosphate-glucose 
(UDP-glucose) while also transferring the UDP from UDP-glucose to galactose. This 
reaction releases glucose-1-phosphate (G1P) which is converted to G6P by 
phosphoglucomutase. G6P then enters the glycolytic pathway. An epimerase converts 
UDP-galactose back to UDP-glucose, ready for the next galactose-phosphate molecule to 
be metabolized.   
 
Pancreas Development and Specification 
In the mouse, pancreatic specification and development begins approximately 8 
days after conception (e8). The pancreatic lineage, marked by expression of Pancreatic and 
Duodenal Homeobox 1 (Pdx1), is derived from the endoderm cell layer, first evidenced by 
a condensation of the mesenchyme by the dorsal gut tube. Subsequent evagination of the 
endoderm into this mesenchyme forms the dorsal pancreatic bud. Approximately 12 hours 
later in, the ventral pancreatic bud begins to form from evagination of the hepatic/biliary 
bud. While this process is morphologically similar to that of the dorsal pancreas, the 
molecular mechanisms promoting ventral pancreas development are distinct (Gittes 2009).  
The dorsal pancreatic bud, which is initially in contact with the notochord, is 
marked by an exclusion of sonic hedgehog (Shh) signaling (Apelqvist et al. 1997). This 
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exclusion is due to activity of the notochord-derived factors Fibroblast Growth Factor 2 
(FGF2) and activin βB. Interestingly, exogenous expression of Shh can override the 
pancreas-inducing effect of activin βB, suggesting that Shh may be an anti-pancreatic 
factor, rather than just a marker of non-pancreatic endoderm (Edlund 1998; Edlund 1999).  
The ventral pancreas forms from ventral endoderm that is never in contact with the 
notochord. FGF signaling from the cardiac mesenchyme promotes liver differentiation 
from the ventral endoderm, while lack of cardiac mesenchyme and FGF signaling promotes 
the default ventral pancreatic fate (Deutsch et al. 2001). Between embryonic days 12 and 
13 in the mouse, the dorsal and ventral pancreatic buds fuse as a result of gut rotation and 
dorsal bud elongation.  
While a few endocrine cells are seen early on (e10), endocrine cell determination 
and proliferation primarily begin after pancreatic bud fusion, in what is termed the 
secondary transition (Bernardo, Hay and Docherty 2008). The decision to become 
endocrine or exocrine pancreas is primarily controlled by Notch signaling (Apelqvist et al. 
1999). The exocrine pancreas, comprised of ducts and acinar cells, is formed by positive 
Notch signaling. The acinar cell fate is promoted through Notch-controlled expression of 
pancreas specific transcription factor 1 (Ptf1a).  Ductal cells initially follow the endocrine 
cell lineage, but Notch activation as well as expression of the transcription factor 
hepatocyte nuclear factor 6 (Hnf6) in a subset of cells destined for endocrine fate (Pax4 
positive) shunts cells into a ductal fate instead of an endocrine one (Greenwood et al. 2007, 
Murtaugh 2007).  
Endocrine cell differentiation is also controlled by Notch signaling, with Notch 
inhibiting the endocrine promoting basic helix-loop-helix (bHLH) transcription factor 
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neurogenin 3 (Ngn3). Downregulation of Notch signaling allows for high expression of 
Ngn3, which promotes a generic endocrine cell fate. Following Ngn3 expression, a variety 
of transcription factors control the specific lineage of the endocrine cells. There are five 
endocrine cell types, glucagon expressing α-cells, insulin expressing β-cells, somatostatin 
expressing δ-cells, ghrelin expressing ε-cells, and pancreatic polypeptide expressing PP 
cells. The first endocrine cells to develop are glucagon positive α-cells.  
After the secondary transition period, endocrine cell clusters begin to form near the 
ductal epithelium (where these lineages are born). There is some debate in the field as to 
whether islets coalesce from migration of individual endocrine cells, or whether large 
clusters of endocrine cells are born at the same place, replicate, and then fission occurs to 
form unique islet clusters (Jo et al. 2011, Herrera et al. 1991). In either case, in mice the 
resulting islets are organized into a core of insulin producing β-cells surrounded by a 
mantle of glucagon producing α-cells. The remaining endocrine cell types are interspersed 
throughout the periphery of the islet. In humans, developing islets are morphologically 
similar to mouse islets, but adult human islets lose the mantle of glucagon cells, and all of 
the endocrine cell types are instead randomly distributed throughout the islet (Cabrera et 
al, 2006). Despite these noted differences in islet organization between species, it is 
generally accepted that islet architecture is developmentally programmed to optimize β-
cell-β-cell interactions as well as β-cell-endothelial cell interactions, and is essential for 
mature islet insulin secretion (Halban et al. 1982, Steiner et al. 2010). Disruption of the 
production or secretion of insulin from β-cells, or a loss in effective insulin response in 
insulin target tissues results in diabetes, a disease affecting millions of people worldwide 
with rapidly increasing prevalence (Guariguata et al. 2014). Additionally, perturbation of 
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islet architecture has also been associated with this disease state (Gepts and Lecompte 
1981). 
 
Tissue-tissue interactions during organogenesis 
Contribution of sympathetic nerves to pancreas development 
Tissue-tissue interactions during development have also been shown to be essential 
for pancreas development (Lammert et al, 2001; Borden et al, 2013). A previous study 
from our lab has demonstrated the necessity of sympathetic innervation in endocrine 
pancreas development (Borden et al. 2013). Loss of sympathetic innervation during 
development, but not adulthood, results in impaired endocrine cell differentiation and 
organization. As β-cell maturation and β-cell-β-cell contacts are required for effective 
glucose-stimulated insulin secretion (GSIS), loss of developmental sympathetic 
innervation also results in ineffective islet function in mature animals. Furthermore, 
pharmacological blockade of β-adrenergic signaling during development phenocopied the 
effects seen following sympathetic denervation, suggesting that the role sympathetic 
neurons play in islet development is through adrenergic signaling.  
Contribution of the vasculature to pancreas development 
Another tissue that contributes significantly to pancreas development is the 
vascular system. A dense vascular network is set up early during neonatal development 
(Johansson et al., 2006a), and plays an instructive role by promoting endocrine cell fates 
while inhibiting exocrine cell fates (Magenheim et al., 2011; Pierreux et al., 2010; Sand et 
al., 2011). As the pancreas matures, the vasculature is skewed towards islets, with vessel 
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density being approximately five times as concentrated within islets compared to exocrine 
tissue (Bonner-Weir and Orci 1982, Konstantinova and Lammert 2004, Brissova et al. 
2006, Murakami et al. 1997, Vetterlein, Petho and Schmidt 1987). This is due to β-cell 
secretion of vascular mitogens, particularly vascular endothelial growth factor-A (Vegf-a), 
which promotes dense intra-islet vascularization (Bergers et al., 2000; Brissova et al., 2006; 
Christofori et al., 1995; Inoue et al., 2002).  During development the primary source of 
Vegf-a is endocrine precursor cells, though Vegf-a production is thought to be restricted to 
β-cells during early neonatal stages (Reinert et al, 2014). Recruitment of endothelial cells 
by Vegf-a is likely through VEGFR-2 (KDR or Flk1), the primary Vegf-a receptor 
expressed in intra-islet endothelial cells (Brissova et al., 2006; Kim et al., 2011). This 
recruitment results in a signaling niche between islet β-cells and intra-islet endothelial cells. 
Signaling from endothelial cells through basement membrane proteins (such as laminins) 
has been shown to influence β-cell proliferation and insulin biosynthesis (Nikolova et al, 
2006).  In mice, hypo- or hyper-vascularization of newly formed islets by β-cell-specific 
deletion (Brissova et al., 2006) or over-expression of Vegf-a (Cai et al., 2012) elicit 
detrimental effects on β-cell mass, insulin secretion, and glucose tolerance, suggesting that 
Vegf-a levels in β-cells must be maintained within a narrow range. Inactivation of Vegf-a 
and subsequent islet hypo-vascularization in adult islets, however, did not perturb islet 
mass and insulin secretion and elicited only modest elevations in blood glucose (D'Hoker 
et al., 2013; Reinert et al., 2013). Together, these studies imply that the influence of the 
intra-islet vasculature and Vegf-a levels on islet morphology and function is predominantly 
exerted during development. Of note, β-cell maturation, which is loosely defined by the 
acquisition of mature β-cell markers, such as Glut2, and the loss of immature β-cell 
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markers, such as Neuropeptide Y (NPY), overlaps with the developmental timing of islet 
vascularization. This suggests that islet vascularization may contribute to islet maturation. 
However, the factors modulating the precise control of β-cell Vegf-a expression, and the 
link between early islet vascular patterning and later metabolic functions, have remained 
poorly defined. 
Here, we identify a pancreas-specific requirement for the β2-adrenergic receptor 
(Adrb2) in controlling glucose homeostasis by suppressing Vegf-a production in β-cells 
and limiting vascular growth in islets during development. Pancreas-specific loss of Adrb2 
results in glucose intolerance and impaired glucose-stimulated insulin secretion, only in 
female mice. The metabolic defects were recapitulated by Adrb2 deletion from neonatal, 
but not adult, β-cells, supporting a role for β-cell Adrb2 during development. We provide 
evidence that Adrb2 acts in β-cells to suppress Vegf-a expression and thus restrict islet 
vascular growth, which in turn, influences insulin synthesis and secretion. Remarkably, 
developmental blockade of Vegf-a signaling corrects islet hyper-vascularization in 
neonatal mice and rescues glucose intolerance and insulin secretion defects in adult Adrb2 
mutant mice. These findings reveal Adrb2 as a negative regulator that controls islet 
development and glucose metabolism by influencing bi-directional communication 















CHAPTER 2: β2-ADRENERGIC 















Adrenergic receptors are prototypical G-protein coupled receptors (GPCRs) that 
respond to adrenal gland-derived epinephrine and nerve-derived norepinephrine to mediate 
a variety of well-documented, acute physiological responses to stress in adult animals. The 
activation of the adrenergic system and the following physiological responses are 
commonly referred to as the “fight or flight” response. The purpose of the fight or flight 
response is to prepare an organism for a physical challenge. As such, many adrenergic 
functions are metabolic and serve to increase the availability of circulating glucose to 
provide energy for the organism. Various organs, such as the liver, pancreas, and adipose 
tissue respond to increased circulating catecholamine levels (by activation of adrenergic 
receptors) to (1) increase liver gluconeogenesis, (2) inhibit pancreatic insulin secretion, and 
(3) increase lipolysis.  
The adrenergic receptors are clustered into two main groups, α and β, based on their 
G-protein coupling. The three β-adrenergic receptors (β1, β2, and β3) are canonically 
coupled to stimulatory G proteins (Gs), whereas, the α-adrenergic receptors are further 
divided into α1 (α1a, α1b, and α1d) and α2 (α2a, α2b, and α2c) receptors, which couple 
with Gq and Gi proteins, respectively (Molinoff, 1984). Norepinephrine is the primary 
ligand for the α-adrenergic receptors, while epinephrine is the primary ligand for the β-
adrenergic receptors. Either ligand can, however, signal through the other class, just with 
lower affinities; β-adrenergic receptors have approximately 100-fold higher affinity for 
epinephrine versus norepinephrine (Molinoff, 1984).  
19 
 
Canonical α1-adrenergic signaling primarily results in contraction of smooth 
muscle cells (Perez, 2006). This occurs through activation of phospholipase C (PLC) via 
Gq proteins, resulting in subsequent cleavage of phosphatidylinositol 4,5-bisphosphate 
(PIP2) into diacylglycerol (DAG) and the temporary intermediate inositol 1,2-cyclic 
phosphodiester, which is rapidly hydrolyzed to inositol triphosphate (IP3). DAG remains 
at the membrane where it acts as a second messenger to activate protein kinase C (PKC), 
while IP3 travels through the cytosol (to the endoplasmic/sarcoplasmic reticulum) to open 
IP3-dependent calcium channels, thus resulting in increased intracellular calcium levels. 
This results in a variety of signaling outcomes depending on the cell type, such as further 
PKC activation or smooth muscle cell contraction (Perez, 2006). PKC activation 
additionally promotes smooth muscle cell contraction, as well as glycogenolysis and 
gluconeogenesis, which both serve to increase available glucose as previously described.  
Canonical α2-adrenergic signaling results in a variety of physiological responses in 
both the nervous system and peripheral tissues. In the nervous system, activation of α2-
adrenergic signaling results in negative feedback of norepinephrine secretion in 
presynaptic sympathetic nerve terminals. This occurs through stimulation of G-protein 
gated potassium (K+) channels that hyperpolarize the neuron, thus inhibiting secretion 
(Perez, 2006). In peripheral tissues, α2-adrenergic activation results in a variety of 
metabolic functions, such as decreased insulin secretion from pancreatic -cells, increased 
glucagon secretion from pancreatic α-cells, inhibition of lipolysis in adipose tissue, and 
inhibition of glycogen breakdown. This occurs through Gi protein inhibition of the 
production of the second messenger, cyclic adenosine monophosphate (cAMP). Inhibition 
of cAMP production occurs when the α-subunit of a Gi protein associates with and inhibits 
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adenylyl cyclase (AC), the enzyme responsible for cAMP production. Protein kinase A 
(PKA) is the primary target of cAMP, and active PKA phosphorylates a number of 
downstream targets, such as crucial metabolic enzymes (pyruvate dehydrogenase) and 
transcription factors (CREB). Inhibition of AC by α2-adrenergic activation results in 
overall inhibition of this pathway.  
 Canonical -adrenergic signaling antagonizes the effects of α2-adrenergic 
signaling, resulting in smooth muscle relaxation, blood vessel dilation, lipolysis, insulin 
secretion from pancreatic -cells, and glycogenolysis and gluconeogenesis in the liver and 
skeletal muscle. These functions are achieved through -adrenergic receptor mediated 
activation of Gs proteins. The α-subunits of Gs proteins associate with and activate AC, 
thus increasing the intracellular cAMP content. The second messenger cAMP then 
activates PKA, which, as mentioned above, phosphorylates a number of downstream 
targets. Targets of PKA in the liver and skeletal muscle include the activation of glycogen 
phosphorylase and inhibition of acetyl-CoA carboxylase, which serves to stimulate 
glycogenolysis. Glycogenesis is inhibited after PKA phosphorylates (and inhibits) 
glycogen synthase.   
Of the -adrenergic receptors, the mechanisms of action of the 2-adrenergic 
receptor (Adrb2) are the most well studied. In contrast with the other -adrenergic 
receptors, studies have revealed that the 2-adrenergic receptor can switch from signaling 
through a Gs to a Gi or Gq depending on the membrane niche, local availability of the G-
proteins, and in a ligand-dependent manner (Wenzel-Seifert and Seifert 2000, Daaka, 
Luttrell and Lefkowitz 1997). However, the full extent of this switching, and the effects 
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that switching has on the outcome of 2-adrenergic receptor signaling are not well 
understood. One of the most well characterized downstream targets of Adrb2 is the L-type 
calcium channel, Cav1.2. Activation of Adrb2 via AC and PKA acutely increases Cav1.2 
activity in the brain and heart (Hell et al, 1993; Fuller et al, 2010).  Additionally, Adrb2 
binding to Cav1.2 has been shown to be necessary for Cav1.2 phosphorylation at residue 
Ser1928, and that this binding is necessary to dissociate Adrb2 from Cav1.2 (Patriarchi et 
al. 2016). Adrb2 and Cav1.2 additionally form a macromolecular complex with trimeric G 
proteins, AC, PKA, and the phosphatase PP2A, which dephosphorylates residues in the 
main PKA activity site (Ser1928) of Cav1.2 (Davare et al. 2001, Hall et al. 2006). Together, 
these interactions are necessary for both activation of Cav1.2 as well as modulation of this 
activation through a negative feedback loop. While this has been well characterized in the 
heart and brain, these interactions have not yet been explored in pancreatic β-cells, even 
though Cav1.2 is known to be a primary calcium channel required for glucose-stimulated 
insulin secretion in these cells.  
While the acute physiological responses to adrenergic signaling have been well 
characterized in adult organisms, the potential role for the adrenergic system during 
development is less well understood. Interestingly, recent evidence has implicated 
adrenergic signaling, specifically β-adrenergic signaling, in contributing to organogenesis 
in rat cardiomyocytes (Rybin et al. 2003). In this study, Adrb2 switching between two 
different Gαs proteins (GαSL and GαSS) occurs during development, and in part contributes 
to differential cAMP accumulation in response to β2-adrenergic stimulation in neonatal 
versus adult cardiomyocytes. Functionally, GαSS has been shown to activate AC more 
effectively than GαSL, effecting cAMP production. However, as the composition of the βγ 
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subunits of G-proteins have been shown to change dramatically with age, it is likely that 
the association of GαSL and GαSS with different βγ subunits additionally affects function 
(Hansen, Schroering and Robishaw 1995). 
  Our lab has previously described a role for β-adrenergic signaling in pancreas 
development.  Pharmacological inhibition of β-adrenergic signaling during early 
development (E18-P6) results in disrupted pancreatic islet morphology during 
development and impaired glucose tolerance in adult mice (Borden et al. 2013). This 
approach did not identify the β-adrenergic receptor(s), but single nucleotide 
polymorphisms (SNPs) in all three β-adrenergic receptors have been correlated with 
obesity and/or metabolic defects (Masuo et al. 2005, Park, Shin and Lee 2008, Lima et al. 
2007). Importantly, of the three β-adrenergic receptors, only Adrb2 is expressed in β-cells 
during embryonic pancreas development, while Adrb1 and Adrb3 are detected postnatally 
and at much lower levels (Berger et al. 2015). Furthermore, global deletion of the β2-
adrenergic receptor in mice results in impaired glucose tolerance (Santulli et al. 2012). 
Combined, this suggests that Adrb2 may play a role in pancreas development and function. 











Expression of Adrenergic Receptors in the Pancreas 
Previous work from our lab has shown that developmental β-adrenergic signaling 
is essential for pancreatic islet development and function (Borden et al, 2013). This was 
done using pharmacological inhibition of β-adrenergic receptors during late gestation 
through early postnatal development (E18-P6). Of the three -adrenergic receptors, Adrb2 
is the most abundantly expressed in -cells during that developmental window (Berger et 
al, 2015). Additionally, it was recently demonstrated that global knockout of the β2-
adrenergic receptor (Adrb2) specifically resulted in impaired islet function in adult mice 
(Santulli et al, 2012). Combined, these results suggest that Adrb2 may be developmentally 
required for endocrine pancreas development and function. 
We first examined the temporal expression of the adrenergic receptors throughout 
pancreatic development. At birth (postnatal day 0 [P0]) as well as in adulthood, all of the 
adrenergic receptors are present, at some level, in the whole pancreas. Mature islets, 
however, express only five of the nine adrenergic receptors, and only two of the three -
adrenergic receptors (Figure 2.1A). Unfortunately, there are no verified antibodies for 
Adrb2, and we were unable to assess cell specificity with immunohistochemistry. Instead, 
to assess the β-cell expression of the 2-adrenergic receptor, we used Fluorescence-
Activated Cell Sorting (FACS) to isolate a pure β-cell population from a mouse line 
expressing GFP under the mouse insulin promoter (MIP-GFP) (Hara et al. 2003). RT-PCR 
from these cells showed robust expression of the 2-adrenergic receptor (Figure 2.1B). We 
were also able to collect non GFP-positive cells representing all other pancreatic cell types. 
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Comparing Adrb2 levels between GFP-positive β-cells and non-β-cells with qPCR 
revealed Adrb2 expression to be approximately 75% lower in non-β-cells compared to β-
cells (Figure 2.1C).  
 
Characterization of mice lacking pancreatic Adrb2 
 To address pancreas-specific functions of Adrb2 during development, we crossed 
mice carrying a floxed Adrb2 allele (Adrb2f/f mice) with transgenic Pdx1-Cre mice, to 
delete Adrb2 in all cells of the pancreatic anlage starting at embryonic stages. Pdx1-
Cre;Adrb2f/f mice (henceforth referred to as Adrb2 cKO mice) were born at expected 
Mendelian frequencies, had normal body weight at birth, no gross morphological 
abnormalities, and survived to adulthood. Efficient Adrb2 deletion was observed from both 
male and female pancreata isolated from Adrb2 cKO mice at postnatal day 6 (P6; Figure 
2.2A). Importantly, quantitative PCR (qPCR) analysis showed that levels of other α- and 
β-adrenergic receptors were unaltered in the absence of Adrb2, indicating that Adrb2 loss 
did not elicit compensatory changes in the expression of other adrenergic receptor genes 
(Figure 2.2A). However, we did note that levels of Adrb2 were approximately 75% lower 
in control male pancreata compared to control female pancreata (Figure 2.2B). Although 
in Pdx1-Cre transgenic mice, Cre recombinase activity has been reported in the 
hypothalamic regions (Song et al., 2010), there is little Adrb2 expression in these areas 
(Allen Brain Atlas, http://mouse.brain-map.org/, Lein et al., 2007). Additionally, the 
(Tg(Pdx1-CreTuv) transgenic mice that we employed have not been reported to carry a 
human growth hormone mini-gene, commonly found in several Cre lines, that elicits 
metabolic defects (Brouwers et al., 2014). 
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Female Adrb2 cKO mice have increased insulin biosynthesis 
Immunohistochemistry (IHC) with the islet hormone markers insulin and glucagon 
revealed that islet shape and cyto-architecture were largely unaffected by pancreatic Adrb2 
loss in neonatal mice, although Adrb2 cKO mice had a greater distribution of smaller islets 
at the expense of larger ones, compared to controls (Figure 2.2 C-D). Endocrine cell 
numbers were unchanged, suggesting that smaller islet size was the result of an 
organizational change, and not a result of increased cell death or defects in cell proliferation 
(Figure 2.2 E). However, we noted a striking increase in insulin immunoreactivity specific 
to female Adrb2 cKO mice, although both male and female mutant mice showed 
comparable Cre-mediated depletion (70% loss) of Adrb2.  In order to determine when the 
increased insulin began, we used immunohistochemistry to examine insulin levels during 
different developmental times, and saw no changes at P0, but a noted increase starting at 
P2 and continuing at P6 (Figure 2.3 A-C).  In agreement with the IHC observations, we 
noted increased Ins2 by qPCR starting at P2 and continuing at P6 in female Adrb2 cKO 
pancreata, with no changes in P6 male Adrb2 cKO pancreata (Figure 2.3 D). Intriguingly, 
control male islets showed higher insulin levels compared to control female islets by IHC 
(see Figure 2.3 C), and qPCR for Ins2 showed significantly higher insulin transcript levels 
in males compared to females (Figure 2.3 E). The enhanced insulin expression in female 
Adrb2 cKO β-cells was additionally seen using ultra-structural analyses, which revealed a 
significant increase in cytoplasmic insulin granule density in Adrb2 cKO β-cells (Figure 
2.3 F-G). Direct stimulation of MIN6 cells, a mouse insulinoma-derived cell line analogous 
to β-cells, with the Adrb2 ligands, epinephrine and norepinephrine, as well as an Adrb2-
specific agonist, salbutamol, did not alter insulin (Ins2) transcript levels, arguing against a 
26 
 
direct effect of Adrb2 signaling on regulating insulin biosynthesis in β-cells (Figure 2.3 
H). Together, these results suggest a female-specific role for Adrb2 in controlling insulin 
expression in neonatal β-cells, likely through an indirect, non-cell-autonomous mechanism.  
 
Female Adrb2 cKO islets have excess vasculature  
Insulin biosynthesis is known to be influenced by paracrine signaling from intra-
islet endothelial cells. Thus, we examined the pancreatic vasculature in neonatal Adrb2 
cKO and control mice using IHC for the endothelial-specific protein, PECAM1 (CD31). 
We observed a pronounced increase in the density of intra-islet endothelial cells in female, 
but not male, Adrb2 cKO islets, similar to the observations for insulin levels. The 
developmental timing was similar to the insulin expression changes, with no differences 
being observed at P0 (Figure 2.4 A), but changes being observed beginning at P2 and 
persisting at P6 in female Adrb2 cKO islets (Figure 2.4 B-D). The vascular abnormality 
appeared to be restricted to islets, as PECAM1 staining in the exocrine pancreas appeared 
grossly normal. Because intra-islet endothelial cells are the sole producers of the vascular 
basement membrane, a specialized extracellular matrix (ECM) consisting of collagen and 
laminin proteins that offer structural support, influence β-cell proliferation and insulin gene 
transcription, we also examined immunoreactivity for Collagen IV and Laminin, two 
abundant markers of the basement membrane. We noted robust increases in both Collagen 
IV and Laminin-411/511 in female Adrb2 cKO islets, while male Adrb2 cKO islets were 
comparable to same-sex control islets (Figure 2.4 E). To further characterize the effects of 
Adrb2 loss on islet micro-vasculature, we used transmission electron microscopy (TEM) 
to visualize islets in female P6 Adrb2 cKO and control mice. Intra-islet capillaries are 
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highly fenestrated to allow for the rapid exchange of nutrients and hormones between islet-
cells and the bloodstream. In the absence of Adrb2, we found that intra-islet endothelial 
cell morphologies were dramatically altered, with a thicker basement membrane, fewer 
fenestrae, and increased caveolae, plasma membrane invaginations that are involved in 
macromolecule transport across endothelial cells and signaling (Figure 2.4 F-H). These 
results suggest that Adrb2 may be important for restricting developmental islet vasculature 
growth. 
 
Loss of pancreatic Adrb2 does not affect islet innervation, ductal morphology, or 
large diameter blood vessels  
Because intra-islet capillaries have been proposed to form a scaffold to promote 
postnatal growth of autonomic fibers, we performed IHC for tyrosine hydroxylase (TH) to 
visualize sympathetic axon innervation in the neonatal pancreas in the absence of Adrb2.  
We found that despite the pronounced increase in intra-islet endothelial cells, sympathetic 
innervation in and around Adrb2 cKO islets was indistinguishable from that in control 
tissues (Figure 2.5 A-B). We additionally examined other pancreatic structures which are 
known to contribute to β-cell development. We saw no changes in female or male Adrb2 
cKO large diameter blood vessels or ducts via IHC with smooth muscle actin (SMA) and 





Islet hyper-vascularization in female Adrb2 cKO islets is likely due to excess Vegf-a 
signaling  
To understand the basis for hyper-vascularized islets in female Adrb2 cKO 
pancreata, we performed qPCR analyses to assess expression of the vascular endothelial 
growth factor family. We observed a marked (3.5-4.7-fold) increase in Vegf-a, the primary 
angiogenic factor produced by β-cells, in female, but not male, Adrb2 cKO pancreata 
starting two days after birth. Interestingly, we also noted increased Vegf-a levels in male 
pancreata compared to female pancreata (Figure 2.6 A). We saw no changes in mRNA 
expression of the other prominent Vegf isoforms, Vegf-b and Vegf-c (Figure 2.6 B). To 
determine if the excess Vegf-a expression is β-cell specific, we crossed Adrb2 cKO mice 
to MIP-GFP mice. Purified β-cells isolated by FACS from female P6 Adrb2 cKO mice 
showed a striking 8-fold increase in Vegf-a transcript levels compared to control β-cells, 
whereas no differences were observed in non β-cell populations between control and Adrb2 
cKO pancreata (Figure 2.6 C-D). Again, we noted no change in Vegf-a levels in male Adrb2 
cKO β-cells, but we did note higher Vegf-a levels in male β-cells compared to female β-
cells (Figure 2.6 C). In addition, we noted lower Adrb2 levels in male β-cells compared to 
female β-cells (Figure 2.6 E). Together, these results suggest that Vegf-a expression and 
intra-islet vasculature are higher in neonatal male islets, which inversely correlate with the 
lower Adrb2 expression compared to females. Adrb2 loss had no effect on Vegf-a 
expression or islet vasculature in neonatal male islets, suggesting that male islets are less 
susceptible to Adrb2 loss compared to females.  
 To address whether Adrb2 activity directly regulates Vegf-a expression, we treated 
MIN6 cells with salbutamol, epinephrine and norepinephrine. Salbutamol and epinephrine 
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treatments significantly suppressed Vegf-a mRNA levels, while norepinephrine had no 
effect, likely because norepinephrine has the lowest affinity of the three agonists for Adrb2 
(Figure 2.6 F). Furthermore, treatment of juvenile islets with salbutamol also suppressed 
Vegf-a levels (Figure 2.6 F). Together, these findings provide evidence of a sexually 
dimorphic function for developmental Adrb2 activity in restricting excessive growth of the 








Figure 2.1. Adrenergic receptor expression in the pancreas. (A) RT-PCR shows all nine 
adrenergic receptors are expressed in both neonatal (postnatal day 0) and adult (6 week) 
pancreata. Isolated islets from adult mice show expression of only five adrenergic 
receptors, including Adrb2. (B) Adrb2 is expressed in β-cells isolated from neonatal 
(postnatal day 6) mice. (C) Adrb2 expression is higher in β-cells than in non-β-cells (n=4, 






Figure 2.2. Analysis of Adrb2 cKO mice at postnatal day 6 (P6). (A) TaqMan qPCR 
shows robust deletion of Adrb2 from Adrb2 cKO pancreata in both females and males. No 
compensatory transcriptional changes are seen in either sex (n=3-4 mice/sex/genotype; one 
sample t-tests **p<0.01, ***p<0.001). (B) Control males have significanly lower Adrb2 
transcript levels than control females (n=4-6 mice/sex; one sample t-test **p<0.01). (C) 
IHC for insulin (magenta) and glucagon (green) reveals preserved endocrine cell 
organization, but smaller islets in Adrb2 cKO pancreata. Scale bar 50µm. (D) 
Quantification of islet size shows significantly more small islets, and significantly fewer 
large islets in Adrb2 cKO pancreata (n=4-6 mice/genotype; one-way ANOVA *p<0.05, 
****p<0.0001). (E) No changes are seen in endocrine cell number between control and 
Adrb2 cKO pancreata, suggesting that smaller islet size is not a result of islet cell death or 
defects in islet cell proliferation, but rather an organizational change (n=4-6 









Figure 2.3. Female Adrb2 cKO mice have increased insulin biosynthesis. (A) 
Immunohistochemistry for insulin reveals no changes in insulin expression at postnatal day 
0 (P0). (B) Insulin immunoreactivity is robustly increased in female Adrb2 cKO islets at 
P2. (C) Insulin immunoreactivity is increased in female Adrb2 cKO islets at P6. Insulin is 
also higher in male controls compared to female controls at P6. No changes are seen 
between male control islets and male Adrb2 cKO islets. Scale bars 50µm. (D) Insulin 
transcript levels are increased in female Adrb2 cKO pancreata starting at P2 and continue 
to increase at P6; no changes are seen in male Adrb2 cKO pancreata at P6 (n=6-10 
mice/sex/genotype; one sample t-tests *p<0.05). (E) Insulin transcript levels are higher in 
male control pancreata compared to female control pancreata at P6 (n=6-7 mice/sex). (F-
G) TEM shows a significant increase in cytoplasmic insulin granule density in female 
Adrb2 cKO β-cells at P6 (n=3 mice/genotype; t-test *p<0.05). Scale bar 2µm. (H) 
Stimulation of MIN6 cells with adrenergic agonists shows no changes in Ins2 transcript 
levels, suggesting increased insulin in female Adrb2 cKO islets is an indirect effect of 






















Figure 2.4. Female Adrb2 cKO islets have excess vasculature. (A) 
Immunohistochemistry for platelet endothelial cell adhesion molecule (PECAM) shows no 
changes in intra-islet vasculature at P0. (B) PECAM density is increased in female Adrb2 
cKO islets at P2. (C) PECAM density remains increased in female Adrb2 cKO islet at P6. 
Male Adrb2 cKO islets are indistinguishable from male control islets, though male control 
islets have denser vasculature than female islets. Scale bars 50µm. (D) Quantification of 
total vessel length (mm) per islet area (mm2). Means ± SEM for n=3 female and male mice 
per genotype. *p<0.05, two-way ANOVA with Bonferroni’s post-test. (E) Female Adrb2 
cKO islets have increased immunoreactivity for the basement membrane markers Collagen 
IV and Laminin. (F-H) TEM shows female Adrb2 cKO islets have a thicker basement 
membrane, fewer fenestrae (arrows), and more caveolae (arrowheads) compared to control 















Figure 2.5 Analysis of pancreatic structures in Adrb2 cKO mice at P6. (A) Tyrosine 
Hydroxylase (TH) immunoreactivity is unchanged surrounding both male and female 
Adrb2 cKO islets. Scale bar 50µm. (B) Quantification of TH density surrounding control 
and Adrb2 cKO islets (n=3-5 mice/genotype; t-test). (C) Large diameter blood vessels, 
marked by FITC-conjugated smooth msucle actin (SMA, green), are unchanged in both 
female and male Adrb2 cKO pancreata. (D) Ducts, marked by rhodamine-conjugated 
dolichos biflorus agglutinin (DBA, red), are unchanged in both female and male Adrb2 










Figure 2.6. Islet hyper-vascularization in female Adrb2 cKO islets is likely due to 
excess Vegf-a signaling. (A) Vegf-a transcript levels are unchanged at P0, peak at P2, and 
remain elevated at P6 in females. Vegf-a is higher in males than females, but unchanged in 
P6 male Adrb2 cKO pancreata (compared to sex- and age-matched controls; n=3-10 
mice/genotype/sex/age; one sample t-tests *p<0.05, **p<0.01, n.s. not significant). (B) No 
changes are seen in other Vegf isoforms (Vegf-b and Vegf-c) in either female or male P6 
Adrb2 cKO pancreata (n=3-5 mice/sex/genotype). (C) Vegf-a is significantly increased in 
β-cells from female Adrb2 cKO mice.  Vegf-a is higher in male β-cells than female β-cells 
(n=4-6 mice/sex/genotype; one sample t-test, t-test *p<0.05). (D) Vegf-a levels are 
unchanged in non-β-cells from female Adrb2 cKO mice (n=5 female mice/genotype). (E) 
Adrb2 levels are lower in male β-cells than female β-cells (n=4 mice/sex; one sample t-test 
*p<0.05). (F) Vegf-a transcript levels are significantly decreased by Salbutamol (SALB), 
or epinephrine (EPI), but not norepinephrine (NE), in MIN6 cells. MIN6 cells were treated 
with each agonist (10µM) for 16 hr. Means ± SEM and expressed as fold-change relative 
to control values. n=3 independent experiments for SALB and NE, 4 independent 
experiments for EPI. *p<0.05, **p<0.01, one-sample t-test. (G) Vegf-a transcript levels are 
significantly decreased by 16-hour Salbutamol (SALB) treatment (10µM) in isolated 









During development, negative regulatory pathways are crucial to counter the un-
restricted growth of tissues/organs. Here, we reveal a previously uncharacterized role for 
β2-adrenergic receptors (Adrb2) in acting as an endogenous “brake” on excessive 
vascularization during islet development. Our findings support a scenario where Adrb2, 
acting in β-cells, suppresses Vegf-a production to limit excessive intra-islet vasculature 
during islet maturation. Islet endothelial cells are critical for regulation of insulin 
biosynthesis and exocytosis in neighboring β-cells. Loss of pancreatic Adrb2 disrupts the 
balance in bi-directional signaling between islet β-cells and endothelial cells, resulting in 
hyper-vascularized islets and enhanced insulin production. A variety of other factors 
previously shown to be differentially expressed in islets over-expressing Vegf-a were also 
affected, highlighting an instructive role for the vasculature in controlling β-cell gene 
transcription. Unexpectedly, we found that the phenotypes of islet vascularization and Ins2 
and Vegf-a overproduction were specific to female mice, revealing an Adrb2-mediated 
sexually dimorphic pathway that underlies islet development.  
In this study, we define a sexually dimorphic role for Adrb2 in controlling islet 
development. Loss of Adrb2 specifically impairs islet vasculature in female mice. The 
molecular underpinnings of sexually dimorphic Adrb2 functions in islets remain to be 
defined, however, β-adrenergic receptor expression and signaling is known to be 
influenced by steroid sex hormones (Marchetti et al., 1994; Yie and Brown, 1995), which 
are known to exert major organizational changes on organogenesis during the first 
postnatal week (McCarthy et al., 2012). Combined with our finding that females have 
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higher basal Adrb2 levels than males during this neonatal period, this suggests that 
testosterone may be inhibiting Adrb2 levels. It is important to consider the alternative that 
estrogen produced from testosterone during this perinatal may be capable of controlling 
Adrb2 expression. Testosterone is converted to estrogen by the cytochrome P450 complex 
called aromatase (Simpson et al, 2005). Although plasma estrogen levels are not 
significantly higher in males than females during the perinatal testosterone surge, estrogen 
levels in different tissues (such as the brain) have been shown to be higher in males during 


















All procedures relating to animal care and treatment conformed to The Johns Hopkins 
University Animal Care and Use Committee (ACUC) and NIH guidelines. Animals were 
group housed in a standard 12:12 light-dark cycle. Mice were maintained on a C57BL/6 
background, or mixed C57BL/6 and 129P, or C57BL/6 and FVB backgrounds. Since 
phenotypes were specific to female mutant mice, animals of both sexes were used for initial 
analyses, and the sex of the animals used are clearly noted throughout the study. Pdx-Cre 
(B6.FVB-Tg(Pdx1-cre)6Tuv/Nci; RRID: IMSR_NCIMR:01XL5) mice were obtained from 
NCI Frederick Mouse Repository. MIP-GFP (B6.Cg-Tg(Ins1-EGFP)1Hara/J; RRID: 
IMSR_JAX:006864) mice were obtained from Jackson Laboratory. Adrb2f/f mice were a 
generous gift from Dr. Gerard Karsenty (Hinoi et al, 2008).  
 
qRT-PCR 
RNA from either whole pancreata (P6) or isolated islets (adult) was isolated using 
TRIzol RNA extraction reagent phenol-chloroform extraction and ethanol precipitation. 
RNA from sorted cells was isolated using Direct-zol RNA Microprep (Zymo) kit. 1.5-2µg 
of total RNA was reverse-transcribed into cDNA with M-MLV Reverse Transcriptase 
(Promega). TaqMan assays (ThermoFisher) were used to quantitatively determine 
transcript levels of the adrenergic receptors, while Maxima SYBR Green/Rox Q-PCR 
Master Mix (ThermoFisher) reagents and primer sets (listed in Primer Table) were used to 
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determine transcript levels for other genes. Both assays were performed in a StepOnePlus 
Real-Time PCR System (ThermoFisher). Fold change in transcript levels was calculated 
using the 2(-ΔΔCt) method, and 18S was used as an endogenous control for normalization.  
 
Morphometric Islet Analysis 
Cryosections were taken from P6 mouse pancreata at 10µm, every 200µm 
throughout the whole pancreas. Sections were washed with PBS, permeabilized in 1% 
Triton X-100 in PBS, and blocked for 1 hour at room temperature using 5% goat serum 
(GS) in PBS + 0.1% Triton X-100. Sections were then incubated overnight at 4°C with a 
guinea pig anti-insulin antibody (1:300) and a mouse IgG1 anti-glucagon antibody (1:500). 
Following PBS washes, sections were then incubated with anti-guinea pig Alexa-546 and 
anti-mouse IgG1 Alexa 488 secondary antibodies (1:200; ThermoFisher). Sections were 
then washed in PBS and mounted in Fluoromount Aqueous Mounting Medium containing 
100µg/mL DAPI. Every islet in the collected sections was imaged on a Zeiss AxioImager. 
The number of α- and β-cells was counted in each islet in each section, and the total α- and 
β-cell number counted was divided by the number of sections imaged to determine average 
endocrine cell number. Islet area was determined using the Region Of Interest manager 
(ROI manager) and the FIJI (FIJI Is Just ImageJ) area measurement tool.  
 
Other IHC 
50µm cryosections were taken from P6 mouse pancreata, then washed with PBS, 
permeabilized in 1% Triton X-100 in PBS, and blocked for 1 hour at room temperature 
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using 5% goat serum (GS) in PBS + 0.1% Triton X-100. Sections were then incubated for 
2 nights at 4°C with either: rat anti-PECAM-1/CD-31 antibody (1:300), rabbit anti-TH 
antibody (1:500), rabbit anti-collagen IV (1:500), or chicken anti-laminin (1:200) in 
conjunction with guinea pig anti-insulin (1:300). Following PBS washes, sections were 
then incubated with anti-rat Alexa-546, anti-rabbit Alexa 488 or 647, anti-chicken 488 or 
647, and anti-guinea pig 488, 546, or 647 secondary antibodies (1:200; ThermoFisher). 
Sections were then washed in PBS and mounted in Fluoromount Aqueous Mounting 
Medium containing 100µg/mL DAPI. Z-stacks of 1µm optical slices were taken using a 
Zeiss LSM 700 confocal microscope equipped with 405, 488, 555, and 633 lasers. 
Maximum intensity projections were generated with FIJI, and quantification of 
sympathetic innervation density was done by calculating integrated TH fluorescence 
density per unit area (FIJI) from multiple random images. Quantification of islet 
vasculature density was done by calculating integrated PECAM-1/CD-31 density per islet 
(ROI set by insulin immunoreactivity) area (FIJI) from multiple random images.  
 
Transmission Electron Microscopy 
Pancreata were dissected and cut into ~1mm3 pieces then fixed in 3% 
formaldehyde + 1.5% glutaraldehyde +2.5% sucrose in 0.1M NaCacodylate + 5mM CaCl2, 
pH 7.4 at room temperature for 1 hour. Pieces were then washed in 2.5% sucrose in 0.1M 
NaCacodylate + 5mM CaCl2 and post-fixed with 1% Palade’s OsO4 for 1 hour on ice, 
followed by incubation in Kellenberger’s uranyl acetate overnight at room temperature. 
Samples were then dehydrated with a graded alcohol series (50%, 75%, 95%, and 100% 
ethanol, then propylene oxide), embedded in Epon, and sectioned (~90nm) and collected 
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onto EM grids. Grids were then imaged using an FEI Tecnai-12 TWIN transmission 
electron microscope operating at 100 kV and a SIS MegaView III wide-angle camera. A 
minimum of three endothelial cells adjacent to at least one -cell were quantified per 
animal, and fenestrae and fused caveolae density was determined for the entirety of the 
endothelial cell.  
 
Cell sorting 
Pancreata from control and Adrb2 cKO animals in a MIP-GFP background were 
digested in 0.05% trypsin, 0.53M EDTA for 15 minutes at 37°C with intermittent 
trituration. Samples were then neutralized with Hank’s Balanced Salt Solution (HBSS, 
Gibco) + 2% FBS, 5mM EDTA, and 10µg/mL DNAse and filtered (70µm). Dissociated 
cells were then sorted using a Sony Biotechnology SH 800 cell sorter, and GFP-positive 
cells separated based on detection using the FL1 channel (absorption 530nm).   
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Sample sizes were similar to those reported in previous publications (Borden et al., 2013; 
Houtz et al., 2016). For practical reasons, analyses of endocrine cell counts and 
quantifications from ultrastructural analyses (caveolae and fenestrae density, insulin 
granule density, insulin granule docking) were done in a semi-blinded manner, such that 
the investigator was aware of the genotypes prior to the experiment, but conducted the 
staining and data analyses without knowing the genotypes of each sample. All Student’s t-
tests were performed assuming Gaussian distribution, two-tailed, unpaired, and with a 
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confidence interval of 95%, with the exception of fold change analyses (such as for qPCR), 
which were done using a one sample t-test. One-way ANOVA analyses with post hoc 
Tukey test or two-way ANOVA analyses with post hoc Bonferroni test were performed 
when more than 2 or 3 groups were compared, respectively. Statistical analyses were based 
on at least 3 independent experiments, and are described in the figure legends. All error 
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Physiology of blood glucose homeostasis 
 Glucose homeostasis is maintained by secretion of the hormone insulin from islets 
of Langerhans in the pancreas. Loss or dysfunction of insulin-producing β-cells in islets 
results in dysregulation of blood glucose levels and leads to diabetes. β-cells receive and 
integrate input from multiple extracellular cues throughout life to control insulin secretion. 
An important goal in diabetes prevention and treatment is a better understanding of the 
molecular and cellular processes governing β-cell development and function. 
In response to nutrient intake, such as ingesting a meal or snack, our blood glucose 
levels rise rapidly due to sugar consumption. This rise is sensed by the -cells of the 
pancreas, which respond by rapidly secreting insulin. Insulin then travels throughout the 
body to insulin responsive tissues, such as the liver, adipose, and skeletal muscle. Insulin 
signaling through the insulin receptor, a canonical receptor tyrosine kinase, in these tissues 
results in the recruitment of GLUT4 glucose transporters from intracellular endosomes to 
the cell membrane (Huang and Czech, 2007). Insertion of these receptors in the cell 
membrane allows for the rapid influx of glucose from the bloodstream, effectively lowering 
the concentration of glucose in the bloodstream. In contrast, when blood glucose levels fall 
too low, such as overnight when the body is in a fasted state, the secretion of insulin from 
-cells is diminished, and glucagon secretion from α-cells is enhanced (Hussain, 2014). 
Glucagon production is negatively regulated by insulin, so when blood glucose levels are 
low, less insulin is produced and secreted, and more glucagon is produced and secreted. 
Glucagon production has also been shown to be positively regulated through adrenergic 
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stimulation (Skoglund, Lundquist and Ahren 1987). Glucagon travels throughout the 
bloodstream and signals through its receptor, a GPCR, to promote gluconeogenesis and 
decrease the rate of glycolysis. This effectively raises the concentration of glucose in the 
bloodstream, bringing it back to a homeostatic state. 
 
Regulation of insulin secretion 
Glucose stimulation 
 The primary stimulator of insulin secretion from pancreatic β-cells is glucose. In 
response to elevated glucose levels in the blood, glucose is brought into β-cells via the 
glucose transporter Glut2 (Thorens et al, 1988; Johnson et al, 1990). Once in the cytoplasm, 
glucose is metabolized through glycolysis, effectively raising the intracellular ATP:ADP 
ratio (see introduction for details). ATP closes ATP-sensitive K+ channels (encoded by 
Kcnj11 and Abcc8), resulting in decreased K+ efflux and rapid depolarization of the β-cell 
plasma membranes. This depolarization serves to open voltage-dependent Ca2+ channels 
(VDCCs), resulting in an influx of calcium ions (MacDonald et al, 2005). Increased 
cytosolic calcium then promotes insulin secretion through activation of synaptotagmins, 
calcium-dependent proteins that bind phospholipids and SNARE proteins to initiate vesicle 
fusion (Gustavsson et al. 2008).    
Regulated insulin secretion from β-cells occurs in two phases, termed first and 
second phase insulin secretion. First phase insulin secretion is an immediate response 
(within five minutes of stimulus), while second phase insulin secretion can be sustained for 
hours after the initial stimulus (MacDonald et al, 2005). It is thought that the two phases 
50 
 
of insulin secretion emanate from two distinct pools of insulin in the cell, a readily 
releasable pool (RRP) located near the plasma membrane that consists of approximately 
1% of the total insulin content of the cell, and a reserve pool located more internally that 
consists of the remaining 99% (Olofsson et al. 2002). These two different granule 
populations allow for both a blunt, rapid initial response as well as a longer, fine-tuned 
response.  
First phase secretion is generated by fusion and release of insulin from docked 
insulin granules. In order to be docked, granules must be tethered to the membrane by a 
complex consisting of Syntaxin1A, Munc18 and granuphilin (Cheviet et al., 2004). It was 
previously believed that docked granules were primed and located at the membrane in order 
to be able to fuse rapidly. Recent studies, however, have shown that the docked granule 
complex, and specifically granuphilin, is inhibitory to secretion (Mizuno et al. 2016). 
Docked granules can be secreted, however, when granuphilin is released in order to allow 
for docked granule fusion. However, the exact mechanisms controlling the release of 
granuphilin in response to glucose are unknown. Granule secretion during the first phase 
of insulin secretion occurs at membrane niches containing already docked granules in close 
proximity with or in complex with L-type calcium channels, such as Cav1.2 (Schulla et al, 
2003, Yang et al, 1999). Granules secreted during the first phase of insulin secretion have 
low calcium sensitivity, and thus need a high local concentration of calcium to be secreted 
(Yang et al, 1999).  
Second phase insulin secretion involves trafficking of more centrally located 
granules to the plasma membrane; movement of granules through the cell requires 
remodeling of the cortical actin cytoskeleton (Nevins and Thurmond, 2003). Our lab has 
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previously shown that this process is, in part, regulated by nerve growth factor (NGF) 
signaling through tropomyosin receptor kinase A (TrkA) (Houtz et al. 2016). NGF-TrkA 
activation results in the internalization of TrkA, which recruits Rac1 to promote F-actin 
reorganization, thus allowing insulin granules to more easily reach the membrane. Calcium 
also contributes to this process by activating gelsolin, an actin-severing protein (Tomas et 
al. 2006). In this way, second phase insulin secretion is more sensitive to calcium, and 
occurs due to overall increased cytosolic calcium levels versus high local concentrations. 
Calcium influx in the second phase of insulin secretion has been shown to be regulated by 
the opening of R-type (and other non L-type) calcium channels, such as Cav2.3 (Jing et al. 
2005). Calcium also plays an important role in insulin granule fusion. Activation of 
synaptotagmin by calcium is essential for forming a SNARE complex and promoting 
granule exocytosis (Gustavsson et al. 2008). Mobilization of intracellular calcium stores 
stimulates ATP synthesis in mitochondria, which further potentiates insulin secretion by 
closing more K+ channels. Glucose-dependent generation of IP3 (Biden et al. 1987), as 
well as incretin actions (described below) are required to mobilize intracellular calcium 
stores. Intracellular calcium stores on their own are not sufficient to promote insulin 
granule exocytosis.  
 
β-adrenergic signaling and acute insulin secretion 
 Adrenergic signaling has long been associated with mediating hormone release 
from the endocrine pancreas. The exact outputs and mechanisms for this acute stimulation, 
however, are still debated. After perfusion of canine pancreata with both α-and β-
adrenergic receptor agonists, glucagon secretion was stimulated while insulin secretion 
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was inhibited (Iversen, 1973). Pharmacological inhibition of α- and β-adrenergic receptors 
in conjunction with catecholamine stimulation suggested that glucagon secretion was being 
stimulated through β-adrenergic signaling, while insulin secretion was being mediated 
through α-adrenergic signaling. Studies in mouse and rat pancreata, however, revealed the 
opposite mechanism. In response to β-adrenergic receptor agonist stimulation with 
isopropylnoradrenaline, insulin secretion was stimulated in a dose-dependent manner 
(Ahren and Lundquist 1981). This secretion was attributed to β2-adrenergic receptors 
specifically, as stimulation with terbutaline (a β2-adrenergic receptor specific agonist) 
additionally stimulated insulin secretion in a dose-dependent manner (Ahren, Jarhult and 
Lundquist 1981, Ahren and Lundquist 1981). Stimulation of insulin secretion with a β1-
adrenergic receptor specific agonist (isopropylaminothiazoloxypropanol [ITP]) was only 
seen in response to high concentrations (Ahren and Lundquist 1981). While these results 
strongly support an acute role for 2-adrenergic receptors in insulin secretion, further 
experiments with selective and non-selective -adrenergic receptor antagonists raised more 
questions. Inhibition of 2-adrenergic receptors with the selective antagonist ICI 118,551 
diminished terbutaline stimulated insulin secretion, but inhibition with the selective 
antagonist butoxamine had no effect, raising the possibility that only a subset of 2-
adrenergic receptors play an acute role in insulin secretion (Ahren and Lundquist 1981). A 
caveat to these studies is that they relied on the measurement of plasma insulin in vivo after 
perfusion or infusion of pharmacological agonists or antagonists. These studies did not 
specifically address the role of insulin secretion versus insulin sensitivity and could not 
rule out off-target effects of stimulating adrenergic receptors signaling in other tissues. This 
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is especially relevant as central nervous system stimulation of adrenergic receptors has 
been implicated in insulin secretion as well (Ribes et al. 1989).  
 Studies from isolated islets have provided more insight into the specific actions of 
adrenergic activity in insulin secretion, though many questions remain. Stimulation of 
isolated male rat islets with the 2-adrenergic receptor specific agonists clenbuterol or 
salbutamol had no effect on insulin secretion in either low or high glucose conditions 
(Lacey et al, 1990). In contrast, stimulation of human islets with these agonists resulted in 
an augmented insulin secretion response that was abrogated by the non-specific -
adrenergic receptor antagonist propranolol (Lacey et al, 1990). Finally, studies from 
isolated male rat islets showed that selective stimulation of 2-adrenergic receptors with 
clenbuterol stimulated glucagon secretion, leading to the conclusion that while in vivo 
stimulation of 2-adrenergic receptors acutely increased plasma insulin levels, the 
mechanism of 2-adrenergic receptor activity in islets was to stimulate glucagon secretion 
in rats (Lacey et al. 1991). In humans, however, 2-adrenergic receptor activity increases 
insulin secretion (Lacey et al, 1993). These results still leave many unanswered questions. 
While the differences between rat and human islets have been noted, mouse islets have 
been less explored. Furthermore, the studies in rat islets were only done from males, while 
many of the human studies were either biased towards one sex or failed to mention the sex 
of the donors altogether. Together, these studies highlight a potential role for β-adrenergic 
signaling in islet hormone secretion and therefore metabolic homeostasis. However, the 
pancreas specific role for Adrb2 in insulin secretion is still unclear. We found that Adrb2 
controls islet vasculature by repressing Vegf-a. As previous studies have shown islet 
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vasculature to be important for islet function (Cai et al, 2012; Reinert et al 2014), we wished 




















Adrb2 contributes to glucose homeostasis  
 Although the global knockout mouse for the β2-adrenregic receptor has been 
previously characterized as having metabolic defects, the published studies only examined 
aged male mice (6-20 months; Santulli et al, 2012). Because we had seen developmental 
changes resulting from pancreas-specific loss of Adrb2, we wanted to know how early the 
metabolic defects arose in Adrb2-/- mice. To characterize the metabolic state of the Adrb2-
/- mice, we examined male and female glucose tolerance. Fed and fasted blood glucose 
levels were unchanged between Adrb2-/- mice and wild types (Figure 3.1 A-B). We did 
observe, however, that male Adrb2+/+ mice had higher fasting blood glucose levels than 
female Adrb2+/+ mice (Figure 3.1 B). Interestingly, both male and female Adrb2-/- mice 
showed slightly enhanced glucose tolerance (Figure 3.1 C-E). Previous studies have shown 
that aged male (6 month and 20-month-old) Adrb2-/- mice have impaired glucose tolerance 
(Santulli et al. 2012), while our mice were only 2 months old. Therefore, it is probable that 
Adrb2-/- mice develop glucose intolerance with age. This interesting metabolic profile also 
suggests that multiple Adrb2-expressing tissues contribute to metabolic homeostasis, likely 
in different ways (i.e. inhibiting insulin uptake in peripheral tissues). While it is possible 
that compensation from Adrb1 (the only other β-adrenergic receptor expressed in islets) 
could confound these results, glucose tolerance tests of adult Adrb1-/- mice showed no 
defects in males or females (shown combined in Figure 3.2 A-B). This suggests that Adrb1 
is dispensable for glucose homeostasis, and likely dispensable for insulin secretion.  
56 
 
Therefore, in order to characterize the pancreatic role for Adrb2 in maintaining glucose 
homeostasis, we further characterized the metabolic profiles of the Adrb2 cKO mice.  
 
Developmental Vegf-a dependent vascular changes persist in Adrb2 cKO adults. 
 We first investigated whether the hyper-vascularization and increased Vegf-a 
expression was maintained in adult Adrb2 cKO females. To do this, we perfused control 
and Adrb2 cKO females with wheat germ agglutinin (WGA) conjugated to an Alexa-488 
fluorophore to paint all the blood vessels within the animals. Indeed, we saw adult Adrb2 
cKO islets maintained excess vascular density (Figure 3.3 A). Additionally, qPCR showed 
a dramatic 11-fold increase in Vegf-a mRNA in female Adrb2 cKO islets, while male islets 
showed control levels of Vegf-a (Figure 3.3 B). 
 
Pancreatic Adrb2 is required for glucose homeostasis 
 In order to determine the metabolic consequences of pancreatic Adrb2 loss, and 
because both excess islet vasculature and blockade of β-adrenergic signaling have been 
shown to result in disrupted metabolic homeostasis (Borden et al., 2013; Cai et al., 2012), 
we performed glucose tolerance tests on mature (2-month-old) Adrb2 cKO animals. 
Interestingly, we saw no glucose tolerance defects in 2-month-old male or female Adrb2 
cKO animals (Figure 3.4A-E). However, we did note that female Adrb2 cKO mice had 
higher fasting glucose levels (Figure 3.4A), an indicator of a pre-diabetic state. Therefore, 
in order to further challenge the Adrb2 cKO mice, the glucose tolerance test was performed 
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with three consecutive glucose challenges. Excitingly, we saw a drastic impairment of 
glucose tolerance in female, but not male Adrb2 cKO mice (Figure 3.4 G-J).  
 Because Adrb2 loss has been associated with age-dependent metabolic phenotypes 
(Santulli et al. 2012), we additionally assessed glucose tolerance in aged (4-month-old) 
male and female Adrb2 cKO mice. Interestingly, we saw glucose tolerance defects in aged 
male and female Adrb2 cKO mice in response to a single glucose challenge (data not 
shown). However, the defects in the female Adrb2 cKO mice were more robust, with the 
change in glucose levels being between 100 and 150mg/dL during the first 30 minutes after 
glucose challenge, while the males differed by only 70 to 90 mg/dL from controls. 
Additionally, aged female Adrb2 cKO mice displayed increased fed blood glucose levels, 
while male Adrb2 cKO fed blood glucose levels were unchanged (data not shown). 
Together, this suggests that the glucose tolerance defects worsen with age in female Adrb2 
cKO mice and, surprisingly, develop late in male Adrb2 cKO mice. This also suggests that 
the mechanism by which Adrb2 influences glucose homeostasis differs in males and 
females.         
 
Pancreatic Adrb2 is required for islet insulin secretion in female mice 
 In order to determine why Adrb2 cKO mice developed glucose intolerance, we 
assessed insulin sensitivity, plasma hormone levels, and insulin secretion. Insulin 
sensitivity was unaffected in male or female Adrb2 cKO mice at both 2 months and 4 
months of age, suggesting that defects in glucose tolerance do not stem from defects in 
insulin responsiveness in female Adrb2 cKO mice, and that insulin hypersensitivity is not 
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masking glucose tolerance defects in male Adrb2 cKO mice (Figure 3.5 A-D). We 
additionally saw no changes in fed or fasted serum glucagon levels in female or male Adrb2 
cKO mice (Figure 3.6 A-B), suggesting that glucose intolerance in Adrb2 cKO mice may 
stem from dysregulation of insulin secretion. To assess this, we first looked at fed and 
fasted plasma insulin levels in male and female Adrb2 cKO mice at 2 and 4 months of age. 
Excitingly, we observed significantly decreased fed plasma insulin levels in 2 and 4-month-
old female, but not male Adrb2 cKO mice (Figure 3.6 C-F). Fasted insulin levels trended 
toward a decrease in female Adrb2 cKO mice, although the effects were statistically not 
significant. Male fasted insulin levels were unchanged. This suggests that although female 
Adrb2 cKO mice produce excess insulin, they are unable to secrete it. Therefore, we 
hypothesized that regulated insulin secretion may also be deficient in female Adrb2 cKO 
mice. To test this, we performed in vivo insulin secretion assays in male and female Adrb2 
cKO mice at 2 and 4 months old. We found significantly dampened glucose-stimulated 
insulin secretion (GSIS) in 2 and 4-month-old female Adrb2 cKO mice compared to same-
sex controls (Adrb2f/f; Figure 3.7 A-D). This suggests that the glucose intolerance seen in 
female Adrb2 cKO mice is due to defective GSIS. While we did not extend our time-course 
to test this, it is possible that male Adrb2 cKO mice would develop defects in GSIS later 
in life, as their glucose tolerance defects were also delayed. It is also possible that the male 
Adrb2 cKO mice become glucose intolerant through a different mechanism, such as 
diminished insulin sensitivity. Further analyses would be needed to uncover the mechanism 
for the glucose intolerance in males.  
 Consistent with the in vivo observations, insulin secretion from isolated female 
Adrb2 cKO islets was significantly dampened, both basally (2.8mM glucose) and in 
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response to high glucose (16.7mM; Figure 3.7E). Insulin content was significantly higher 
in female Adrb2 cKO islets, consistent with the developmental findings, and suggesting 
that insulin secretion is not diminished due to a decrease in insulin biosynthesis (Figure 
3.7F). Together, these results suggest that pancreatic Adrb2 is required for glucose 
tolerance and islet insulin secretion in female mice.  
 
Loss of Adrb2 perturbs islet calcium responses and exocytosis 
Regulation of glucose-stimulated insulin secretion (GSIS) occurs at many levels in 
the β-cell, including glucose uptake and metabolism, membrane depolarization, calcium 
responsiveness, and insulin granule docking and fusion (MacDonald et al., 2005). To 
understand which step in GSIS requires Adrb2, we first assessed levels and localization of 
Glut2, the β-cell glucose transporter by IHC. We saw diminished overall expression of 
Glut2, suggesting that the GSIS defects in female Adrb2 cKO islets may be due to an 
inability to sense high glucose levels (Figure 3.8 A). To assess if this was the primary cause 
of the diminished insulin secretion, we next exposed female islets to a high extracellular 
concentration of potassium (30mM KCl) to depolarize the β-cell plasma membranes and 
open voltage-dependent calcium channels (VDCCs), thus bypassing the need for glucose 
uptake and metabolism in insulin secretion (Hatlapatka et al., 2009). Islets from female 
Adrb2 cKO mice had significantly diminished KCl-stimulated insulin secretion, suggesting 
Adrb2 affects steps of GSIS after membrane depolarization in addition to affecting Glut2 
levels (Figure 3.8 B). To further assess the role for Adrb2 in GSIS, we used TEM to 
examine insulin granule docking at the plasma membrane in response to glucose. Control 
animals showed significant recruitment of insulin granules to the plasma membrane (within 
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50nm of apical plasma membrane) following glucose injection compared to the fasted state 
(Figure 3.8 C-D). However, Adrb2 cKO β-cells had significantly fewer docked insulin 
granules following glucose injection compared to glucose-injected controls, and showed 
no significant recruitment compared to the fasted state (Figure 3.8 C-D). These data suggest 
a requirement for Adrb2 downstream of glucose sensing and membrane depolarization, 
likely in calcium signaling or insulin granule mobility.  
To further assess potential mechanistic defects in female Adrb2 cKO islets, we 
assessed overall cAMP levels, as Adrb2 is thought to increase cAMP levels when signaling 
through a Gs protein, and thus promote insulin secretion in response to high glucose in this 
manner. Indeed, we saw significantly decreased levels of cAMP in female Adrb2 cKO 
islets (Figure 3.9 A). This suggested that loss of Adrb2-cAMP signaling may contribute to 
the loss of GSIS. However, cAMP is not thought to play a primary role in basal insulin 
secretion, and as we saw defects in fed plasma insulin levels and islet insulin secretion in 
low glucose, we wanted to probe the insulin secretion defects further, as it was unlikely 
that decreased cAMP levels was the only cause of all the GSIS defects. To address whether 
Adrb2 is required for glucose-dependent calcium response in β-cells, we loaded isolated 
islets with Fluo-4 AM, which fluoresces upon binding to calcium, and treated them with 
low glucose, high glucose, and KCl (Kenty and Melton, 2015). In response to high glucose 
(20mM) and subsequent KCl-stimulated membrane depolarization (30mM), control islets 
showed a significant increase in intracellular calcium (Figure 3.9 B-C). In contrast, islets 
from Adrb2 cKO mice showed a significantly diminished calcium response in both 
conditions (Figure 3.9 B-C).  
61 
 
In order to assess the underlying cause of the diminished calcium response, we 
screened islets for transcripts encoding proteins involved in various GSIS events. We did 
not see changes in expression of glycolysis genes (Aldob, Pfkl, Ldha, Tpi, or Pklr) or 
potassium channel subunit genes (Kcnj11 or Abcc8; Figure 3.9 D). Interestingly, we found 
down-regulation of genes involved in calcium-response during GSIS, including the L-type 
calcium channel (Cacna1c [Cav1.2]). We also saw significant down-regulation of Snap25, 
Rph3al (Noc2), and Pclo (Piccolo), which promote insulin granule exocytosis (Figure 3.9 
D). Specifically, Noc2 interacts with components required for insulin granule exocytosis, 
such as those of the Rab and Munc family (Cheviet et al., 2004) and Piccolo is a scaffold 
protein that links ATP-gated potassium channels, L-type calcium channels (such as 
Cav1.2), and insulin granules to promote GSIS (Shibasaki et al., 2004). This was of 
particular interest to us because Rph3al and Pclo have been shown to be controlled in β-
cells by the transcription factor Neurod1 (Gu et al., 2010), and we had previously noted 
significantly decreased levels of Neurod1 in P6 Adrb2 cKO pancreata (not shown). 
Therefore, we also assessed Neurod1 levels in isolated adult islets and found a significant 
decrease in female Adrb2 cKO islets. Neurod1 is thought to be a regulator is β-cell 
maturation (Gu et al., 2010), so we assessed levels of other maturity markers in Adrb2 cKO 
islets. While we saw no changes in some markers (the transcription factors Nkx5.1 and 
Pdx1, or Urocortin 3 [Ucn3]), we did note a significant increase in Neuropeptide Y (NPY; 
Figure 3.9D). NPY is of interest as it is a marker of immature β-cells that is thought to play 
a role in inhibiting insulin secretion via inhibition of adenyl cyclase activity (Motulsky and 
Michel, 1988). While loss of Adrb2-Gs signaling could be the cause of the decreased cAMP 
levels we saw in Adrb2 cKO islets, increased NPY may also contribute to decreased cAMP 
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levels. We additionally noted diminished Slc2a2 (Glut2) levels, as seen with IHC 
previously (Figure 3.9 D). This transcriptional profile suggests that female Adrb2 cKO β-
cells may be functionally immature and may have diminished insulin secretion due to not 
only dampened cAMP response, but also decreased expression of calcium-response GSIS 
genes, and failure to form the insulin secretion complex.  
 
Adrb2 is not required for GSIS in adult islets 
 We next asked whether Adrb2 is required in β-cells to regulate insulin secretion 
and glucose homeostasis. Therefore, we crossed floxed Adrb2 (Adrb2f/f) mice with 
transgenic mice expressing tamoxifen-inducible Cre-ER fusion protein driven by the Pdx1 
promoter (Tg(Pdx1-cre/Esr1*)Dam) (Gu, 2002). Pdx1 expression is restricted to β-cells and 
somatostatin-expressing δ-cells after birth (Guz, 1995; DiGruccio, 2016). Thus, tamoxifen-
induced Cre activity at postnatal stages should allow for inducible ablation of Adrb2 in β-
cells, as well as δ -cells, in Pdx1-cre/Esr1*Dam;Adrb2f/f mice (henceforth referred to as 
Adrb2 i-cKO  mice). Tamoxifen was administered subcutaneously to adult (5-6 week old) 
female mice, and glucose tolerance and islet insulin secretion was tested 4 weeks after the 
final injection (Figure 3.10 A). Tamoxifen significantly induced deletion of Adrb2 from 
Adrb2 i-cKO islets (Figure 3.10 B). No changes were seen in glucose tolerance, in vivo 
insulin secretion, or islet GSIS in female tamoxifen-treated Adrb2 i-cKO mice (Figure 3.10 
C-F), suggesting that Adrb2 is dispensable for the control of GSIS in adulthood. Because 
we had seen more pronounced glucose tolerance defects in aged mice, and in both males 
and females, we also used the Adrb2 i-cKO mice to assess the requirement for Adrb2 in 
aged islets (Figure 3.11 A). Again, we saw significant deletion of Adrb2 from Adrb2 i-
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cKO islets (both male and female had similar deletion; Figure 3.11 B). We saw no defects 
in glucose tolerance in either female or male Adrb2 i-cKO mice, further suggesting that 
Adrb2 is dispensable for control of glucose homeostasis in adult mice (Figure 3.11 C-F).  
 
Adrb2 is required in β-cells for metabolic homeostasis 
Because the Adrb2 cKO mice are a pan-pancreatic deletion, and the Adrb2 i-cKO 
mice are a β-cell specific deletion, there is also a possibility that Adrb2 is required (for islet 
GSIS) in non-β-cells. To address this, we administered tamoxifen to neonatal (P0-P1) 
female Adrb2 i-cKO mice to delete Adrb2 from β-cells before we saw it to be required in 
the pancreas (Figure 3.12 A). We then let the mice grow to 2 months of age. We saw 
efficient deletion of Adrb2 in islets isolated from neonatally injected Adrb2 i-cKO mice 
(Figure 3.12 B). Excitingly, we also saw defects in glucose tolerance and in vivo insulin 
secretion similar to those seen in Adrb2 cKO mice, suggesting that the defects seen in 
Adrb2 cKO mice were indeed due to loss of Adrb2 from β-cells (Figure 3.12 C-F). This 
also further suggests that Adrb2 is developmentally required, but not required in the adult 



























Figure 3.1. Global Adrb2 knockout mice have slightly dampened glucose response at 
2 months of age. (A-B) Fed and fasted blood glucose levels are unchanged in male and 
female mice lacking the β2-adrenergic receptor. Male mice have significantly higher fasted 
blood glucose levels than female mice. Means for n= 5-10 mice/sex/genotype; one-way 
ANOVA with Tukey’s post-test **p<0.01). (C-D) Glucose tolerance is enhanced in (C) 
female and (D) male Adrb2-/- mice. Mean ± SEM for n= 8 female mice/genotype, 10 male 
control and 5 male Adrb2-/- mice. (E) Area under the curve (AUC) for female and male 












Figure 3.2. Global loss of Adrb1 does not affect glucose tolerance. (A) Glucose 
tolerance test shows no changes in glucose levels following glucose challenge in mice 
lacking Adrb1. Means ± SEM for n= 5-6 mixed sex mice/genotype.  (B) Area Under the 






Figure 3.3 Developmental Vegf-a dependent vascular changes persist in Adrb2 cKO 
adults. (A) Wheat Germ Agglutinin (WGA) vessel painting shows hyper-vascularization 
persists in adult female Adrb2 cKO islets (outlined in white). Scale bar 50µm. (B) Vegf-a 
mRNA levels are significantly increased in islets isolated from adult female Adrb2 cKO 












Figure 3.4. Glucose tolerance of 2-month-old Adrb2 cKO mice. (A) Neither female nor 
(B) male Adrb2 cKO mice show glucose tolerance defects in response to a single glucose 
challenge.  Female Adrb2 cKO mice have significantly higher fasted blood glucose levels 
compared to same-sex controls. Means ± SEM for n= 9-10 mice/sex/genotype; t-tests 
*p<0.05. (C) AUC for female glucose tolerance. (D) Fed blood glucose levels are 
unchanged between female control and Adrb2 cKO mice. (E) AUC for male glucose 
tolerance. (F) Fed blood glucose levels are unchanged between male control and Adrb2 
cKO mice. (G) In response to three consecutive glucose challenges, female Adrb2 cKO 
mice display significant defects in glucose tolerance. Means ± SEM for n= 6-7 
mice/genotype; t-tests *p<0.05, ***p<0.001. (H) AUC for female three injection glucose 
tolerance (*p<0.05, t-test). (I)  Male Adrb2 cKO mice display normal glucose tolerance in 
response to three consecutive glucose challenges. Means ± SEM for n= 6-9 mice/genotype. 















Figure 3.5. Insulin sensitivity is unaffected by pancreatic Adrb2 loss. (A) 2-month-old 
female and (B) male Adrb2 cKO mice are insulin sensitive. Means ± SEM for n =3-6 
mice/genotype/sex; one sample t-tests **p<0.01, ***p<0.001). (C) Insulin sensitivity is 
maintained in 4-month-old female and (D) male Adrb2 cKO mice. Means ± SEM for n= 






Figure 3.6 Insulin and glucagon levels in female and male Adrb2 cKO mice. (A) Fed 
and fasted serum glucagon levels are unchanged in female and (B) male Adrb2 cKO mice. 
Means ± SEM for n= 3-6 mice/genotype/sex; two-way ANOVA with Bonferroni’s post-
test, n.s. not significant. (C) Fed plasma insulin levels are significantly reduced in female 
Adrb2 cKO mice at 2 months of age. Means ± SEM for n= 10-11 mice/genotype; two-way 
ANOVA with Sidak’s post-test, *p<0.05. (D) Neither fed nor fasted plasma insulin levels 
are changed in 2-month-old male Adrb2 cKO mice. Means ± SEM for n =8-10 
mice/genotype; two-way ANOVA with Sidak’s post-test. (E) Fed plasma insulin levels 
remain significantly reduced in female Adrb2 cKO mice at 4 months of age. Means ± SEM 
for n= 7-9 mice/genotype; two-way ANOVA with Sidak’s post-test, *p<0.05. (F) Fed and 
fasted plasma insulin levels are unchanged in 4-month-old male Adrb2 cKO mice. Means 













Figure 3.7 Insulin secretion is impaired in female Adrb2 cKO mice. (A) Insulin 
secretion in response to a glucose challenge is significantly impaired in 2-month-old 
female, but not (B) male Adrb2 cKO mice. Means ± SEM for n= 5-8 mice/genotype/sex; 
t-tests, *p<0.05. (C) Insulin secretion remains impaired in 4-month-old Adrb2 cKO female 
and unchanged in (D) 4 month old male Adrb2 cKO mice. Means ± SEM for n= 8-11 
mice/sex/genotype; t-tests, *p<0.05, **p<0.01. (E) Insulin secretion from isolated female 
Adrb2 cKO islets is significantly dampened both basally and in response to glucose 
challenge. Means ± SEM for n= 4-6 mice/genotype; two-way ANOVA with Bonferroni’s 
post-test, **p<0.01, ****p<0.0001). (F) Insulin content is significantly increased in female 














Figure 3.8. Loss of Adrb2 diminishes Glut2 levels and insulin exocytosis. (A) Glut2 
levels are decreased in female Adrb2 cKO islets. Scale bar 25µm. (B) Potassium-stimulated 
insulin secretion is significantly diminished in isolated islets from female Adrb2 cKO mice. 
means ± SEM for n= 4-5 mice/genotype; two-way ANOVA with Bonferroni’s post-test, 
*p<0.05, ****p<0.0001. (C) Ultrastructural analysis of insulin granule docking reveals 
Adrb2 is necessary for glucose-stimulated surface localization of insulin granules in female 
β-cells. Docked insulin granules (within 50nm of apical plasma membrane) are indicated 
by red arrowheads. Scale bar 1 µm. (D) Quantification of granule docking per micrometer 
of plasma membrane. Means ± SEM for n= 3 mice/genotype/condition; two-way ANOVA 




Figure 3.9. Defects in calcium signaling in Adrb2 cKO islets. (A) cAMP levels are 
significantly decreased in female Adrb2 cKO islets. Means ± SEM for n= 3-4 
mice/genotype; t-test *p<0.05. (B) Representative images from movies of control and 
Adrb2 cKO islets loaded with Fluo-4 in response to low glucose, high glucose, and 
potassium chloride shows diminished calcium response in female Adrb2 cKO islets. Scale 
bar 50µm. (C) Quantification of intracellular calcium (normalized Fluo-4 intensity) area 
under the curve in response to high glucose and potassium chloride. Means ± SEM for n= 
3 mice/genotype, 10 cells per mouse; t-tests of AUC, *p<0.05). (D) Female Adrb2 cKO 
islets have decreased expression of genes involved in GSIS. Means ± SEM for n= 3-5 









Figure 3.10. Deletion of Adrb2 from 2-month-old adult β-cells does not affect glucose 
homeostasis or insulin secretion. (A) Schematic for tamoxifen-inducible deletion of 
Adrb2 from adult β-cells. (B) Adrb2 mRNA levels are significantly diminished in Adrb2 i-
cKO islets following tamoxifen administration. n=3 mice/condition; one sample t-test, 
*p<0.05. (C) Glucose tolerance is unaffected in females following adult-deletion of β-cell 
Adrb2. Means ± SEM for n= 5-7 mice/condition. (D) Area under the curve (AUC) for 
glucose tolerance. (E) In vivo insulin secretion is unchanged in Adrb2 i-cKO mice. Means 
± SEM for n= 5-6 mice/condition. (F) Islet insulin secretion is normal in female Adrb2 i-



















Figure 3.11. Deletion of Adrb2 from 4-month-old adult β-cells does not affect glucose 
homeostasis or insulin secretion. (A) Schematic for tamoxifen-inducible deletion of 
Adrb2 from adult β-cells. (B) Adrb2 mRNA levels are significantly diminished in Adrb2 i-
cKO islets following tamoxifen administration. Deletion was 60-80% independent of sex. 
n=3 mice/condition of mixed sex; one sample t-test, *p<0.05). (C) Glucose tolerance is 
unaffected in females following 4-month-old adult-deletion of β-cell Adrb2. Means ± SEM 
for n= 7 mice/condition. (D) Area under the curve (AUC) for female glucose tolerance. (E) 
Glucose tolerance is unaffected in males following 4-month-old adult-deletion of β-cell 


















Figure 3.12. Deletion of Adrb2 from neonatal female β-cells impacts glucose 
homeostasis and insulin secretion. (A) Schematic for tamoxifen-inducible deletion of 
Adrb2 from neonatal β-cells. (B) Adrb2 mRNA levels are significantly diminished in 
female Adrb2 i-cKO islets following tamoxifen administration. n=3 female mice/condition; 
one-sample t-test, *p<0.05. (C) Neonatal deletion of Adrb2 from female β-cells results in 
glucose intolerance. Means ± SEM for n= 5-7 mice/condition. (D) Area under the curve 
(AUC) for female glucose tolerance. t-test, *p<0.05. (E) Fed plasma insulin levels are 
lower in female Adrb2 i-cKO mice. Means ± SEM from n= 3-4 female mice/condition; t-
test, *p<0.05). (F) In vivo glucose-stimulated insulin secretion is diminished in Adrb2 i-













Table 2. Primer sets used in Chapter 3. 
Oligonucleotides 
Sequence Source Identifier 
Ins2-F: 5’-TGTCAAGCAGCACCTTTGTG-3’ This paper  
Ins2-R: 5’-ACATGGGTGTGTAGAAGAAGCC-3’ This paper  
Adrb2-F: 5’-GGGAACGACAGCGACTTCTT-3’ This paper  
Adrb2-R: 5’-GCCAGGACGATAACCGACAT-3’ This paper  
Vegf-a-F: 5’-GCACATAGAGAGAATGAGCTTCC-3’ Ford et al, 2011  
Vegf-a-R: 5’-CTCCGCTCTGAACAAGGCT-3’ Ford et al, 2011  
Aldob-F: 5’- AGAAGGACAGCCAGGGAAAT-3’ Gu et al, 2010  
Aldob-R: 5’- GTTCAGAGAGGCCATCAAGC-3’ Gu et al, 2010  
PFKL-F: 5’- GCTGCAATGGAGAGTTGTGA-3’ Gu et al, 2010  
PFKL-R: 5’- GGATGTTGAAAGGGTCCTCA-3’ Gu et al, 2010  
LDHA-F: 5’- TGTCTCCAGCAAAGACTACTGT-3’ Gu et al, 2010  
LDHA-R: 5’- GACTGTACTTGACAATGTTGGGA-3’ Gu et al, 2010  
TPI-F: 5’- CCAGGAAGTTCTTCGTTGGGG-3’ Gu et al, 2010  
TPI-R: 5’- CAAAGTCGATGTAAGCGGTGG-3’ Gu et al, 2010  
PKLR-F: 5’- TCAAGGCAGGGATGAACATTG-3’ Gu et al, 2010  
PKLR-R: 5’- CACGGGTCTGTAGCTGAGTG-3’ Gu et al, 2010  
Kcnj11-F: 5’- AGGGCATTATCCCTGAGGAA -3’ Harvard Primer Bank ID 6754426a1 
Kcnj11-R: 5’- TTGCCTTTCTTGGACACGAAG-3’ Harvard Primer Bank ID 6754426a1 
Abcc8-F: 5’- TCAACTTGTCTGGTGGTCAGC-3’ Gu et al, 2010  
Abcc8-R: 5’- GAGCTGAGAAAGGGTCATCCA-3’ Gu et al, 2010  
Cacna1c-F: 5’-ATGAAAACACGAGGATGTACGTT-3’ Harvard Primer Bank ID 6753228a1 
Cacna1c-R: 5’-ACTGACGGTAGAGATGGTTGC-3’ Harvard Primer Bank ID 6753228a1 
Cacna1d-F: 5’- AGAGGACCATGCGAACGAG-3’ Harvard Primer Bank ID 20338999a1 
Cacna1d-R: 5’- CCTTCACCAGAAATAGGGAGTCT-3’ Harvard Primer Bank ID 20338999a1 
Snap25-F: 5’- CAACTGGAACGCATTGAGGAA-3’ Harvard Primer Bank ID 6755588a1 
Snap25-R: 5’- GGCCACTACTCCATCCTGATTAT-3’ Harvard Primer Bank ID 6755588a1 
Stx1A-F: 5’- AGAGATCCGGGGCTTTATTGA-3’ Harvard Primer Bank ID 15011853a1 
Stx1A-R: 5’- AATGCTCTTTAGCTTGGAGCG-3’ Harvard Primer Bank ID 15011853a1 
Pclo-F: 5’-TACTCGGACCCATTTGTGAA-3’ Gu et al, 2010  
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Pclo-R: 5’-TACTGTTTGATTCCACTCGGGATT-3’ Gu et al, 2010  
Rph3al-F: 5’-GCAGTGGAAATGATCAGTGG-3’ Gu et al, 2010  
Rph3al-R: 5’-TCAGGCACTGGCTCCTCCTC-3’ Gu et al, 2010  
Neurod1-F: 5’- ATGACCAAATCATACAGCGAGAG-3’ Harvard Primer Bank ID 33563268a1 
Neurod1-R: 5’- TCTGCCTCGTGTTCCTCGT-3’ Harvard Primer Bank ID 33563268a1 
Nkx5.1-F: 5’-CTGCACAGTATGGCCGAGATG-3’ Harvard Primer Bank ID 21450629a1 
Nkx5.1-R: 5’CCGGGTTATGTGAGCCCAA-3’ Harvard Primer Bank ID 21450629a1 
Npy-F: 5’-AGAGATCCAGCCCTGAGACA-3’ Gu et al, 2010  
Npy-R: 5’-GATGAGGGTGGAAACTTGGA-3’ Gu et al, 2010  
Pdx1-F: 5’-CCCCAGTTTACAAGCTCGCT-3’ Harvard Primer Bank ID 22122647a1 
Pdx1-R: 5’-CTCGGTTCCATTCGGGAAAGG-3’ Harvard Primer Bank ID 22122647a1 
Ucn3-F: 5’-AAGCCTCTCCCACAAGTTCTA-3’ Harvard Primer Bank ID 21492632a1 
Ucn3-R: 5’-GAGGTGCGTTTGGTTGTCATC-3’ Harvard Primer Bank ID 21492632a1 
Slc2a2-F: 5’-TCAGAAGACAAGATCACCGGA-3’ Harvard Primer Bank ID 13654262a1 
Slc2a2-R: 5’-GCTGGTGTGACTGTAAGTGGG-3’ Harvard Primer Bank ID 13654262a1 
18SrRNA-F: 5’-CGCCGCTAGAGGTGAAATTC-3’ Park et al, 2016  














Here we demonstrate that pancreatic Adrb2 is essential for insulin secretion and 
long-term glycemic control, and our results support a causal relationship between the early 
developmental perturbations in islet vasculature and the later functional deficits in Adrb2 
cKO mice. However, the precise molecular mechanisms by which Adrb2 regulates Vegf-a 
production in β-cells remain to be determined. Adrb2 is activated both by circulating 
epinephrine, derived from adrenal glands, and norepinephrine, secreted locally by 
sympathetic nerves, although Adrb2 has 100-fold higher affinity for epinephrine (Molinoff, 
1984). Our findings that epinephrine, but not norepinephrine, suppressed Vegf-a 
expression in MIN6 cells, together with observations of differences in phenotypes between 
Adrb2 cKO and sympathectomized mice (Borden et al., 2013), suggest that epinephrine is 
the likely ligand responsible for Adrb2-mediated effects on Vegf-a levels and islet 
vasculature. Adrb2 is a prototypical GPCR that is classically thought to couple with Gαs 
proteins and activate transcriptional events via a cAMP-PKA-CREB pathway, which 
stimulates Vegf-a expression in several cell types (Claffey et al., 1992; Lee et al., 2009; 
Wu et al., 2007). However, association of GPCRs with specific Gα proteins is dependent 
upon the cellular context. Our findings suggest that in pancreatic β-cells, Adrb2 might act 
via Gαi to negatively regulate cAMP-mediated transcriptional signaling and thus repress 
Vegf-a levels. In support of this idea, loss of Adrb2 enhanced CREB phosphorylation in 
bone osteoblasts (Kajimura et al., 2011). However, we did note decreased cAMP levels in 
adult Adrb2 cKO islets, which may suggest that Adrb2 acts through a Gαs to positively 
mediate cAMP levels. However, due to the significant transcriptional changes, specifically 
the robust increase in NPY, which is known to inhibit cAMP signaling (Motulsky and 
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Michel, 1988), we believe that the decreased cAMP levels are a secondary consequence of 
increased NPY, and not a direct result of Adrb2 loss. More studies would be necessary to 
further elucidate this signaling pathway. 
Vascular endothelial cells instruct β-cell gene expression and maturation, by 
supplying extracellular matrix molecules and soluble factors including hepatocyte growth 
factor and thrombospondin-1 (Eberhard et al., 2010; Hogan and Hull, 2017; Johansson et 
al., 2009; Johansson et al., 2006b; Olerud et al., 2011). In neonatal Adrb2 cKO islets, we 
observed an upregulation of insulin expression, in agreement with previous reports of 
endothelial cells regulating insulin gene transcription via producing vascular basement 
membrane proteins (Kaido et al., 2004; Nikolova et al., 2006; Nikolova et al., 2007). Given 
the enhanced insulin biosynthesis in Adrb2 cKO islets, the decrease we observed in mature 
β-cell secretory function is even more striking. We reason that this is due, in part, to 
reduced expression of genes associated with calcium responsiveness and exocytosis. It is 
unclear if these changes reflect compensatory efforts to counter excessive insulin 
production and protect against hypoglycemia, or a bonafide effect of endothelial cells in 
instructing mature β-cell phenotype. It is also plausible that enhanced insulin content in 
Adrb2 cKO islets is a result of a build-up of insulin granules that are unable to be secreted.   
Of note, in contrast to previous studies where Vegf-a over-expression and islet 
vascular hypertrophy is accompanied by β-cell loss, we did not observe major disruptions 
in β-cell mass or islet architecture in Adrb2 cKO animals (Agudo et al., 2012; Brissova et 
al., 2014; Cai et al., 2012). This could reflect differences in the timing and levels of Vegf-
a over-expression elicited by Adrb2 loss versus transgenic over-expression of Vegf-a. 
Early increases in Vegf-a expression and islet vascular density preceding the onset of 
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hyperglycemia have been observed in animal models of type 2 diabetes (Li et al., 2006). 
An expanded islet capillary network has also been noted in human islets from individuals 
with type 2 diabetes (Brissova et al., 2015), although the patterning and density of the 
human islet micro-vasculature differs significantly from that in rodents (Brissova et al., 
2015). Together, these studies underscore the need to fully delineate the pathways 
underlying the tight control of β-cell-endothelial cell communication and their long-term 
impact on islet function. 
Our results support a causal relationship between the early developmental 
perturbations in islet vasculature and the later functional deficits in Adrb2 cKO mice. That 
Adrb2 loss from mature β-cells did not impair insulin secretion was surprising in the 
context of previously reported effects of β2-adrenergic agonists on acutely stimulating 
insulin release from adult islets (Ahren and Schersten, 1986; Lacey et al., 1993). Thus, in 
adult islets, the effects of Adrb2 agonists on insulin release are likely indirect, perhaps via 
regulating glucagon release from α-cells (Ahren and Schersten, 1986), or suggest species-
specific differences in adult Adrb2 functions in β-cells. The effects of Adrb2 on neonatal 
islet vascularization overlap with the current model of β-cell maturation (Qiu et al, 2017). 
This suggests that intra-islet vasculature may play an instructive role in promoting β-cell 
maturation, and that Adrb2 may be a major regulator of this process. Previous studies have 
shown that islet Adrb2 levels decline over time, and it was hypothesized that the age-related 
loss contributes to adult phenotypes (Berger et al, 2015; Santulli et al, 2012). While we 
additionally note Adrb2 levels diminishing in adult islets, we hypothesize that this is 
because Adrb2 is no longer required in adult islets. Our study reveals that β-cell Adrb2 is 
required in neonates for long-term glycemic control. In contrast, Adrb2 in adult β-cells is 
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dispensable for glucose tolerance and insulin secretion. Together with the declining 
expression data, this suggests that the primary role for β-cell Adrb2 is in programming 
neonatal islet vasculature, and that Adrb2 levels decline with age because Adrb2 is no 
longer required.  
β-adrenergic receptors have been best characterized for mediating diverse 
physiological responses to stress in adult mammals and are one of the most common targets 
of therapeutic drugs. β-adrenergic receptor antagonists (β-blockers) are commonly used to 
treat cardiovascular disease and hypertension, including in pregnant women (Easterling, 
2014; Parati and Esler, 2012; Sharma et al., 2001), and administered to infants for treating 
hemangiomas (Chinnadurai et al., 2016). Our findings in mice suggest that inhibition of 
















All procedures relating to animal care and treatment conformed to The Johns Hopkins 
University Animal Care and Use Committee (ACUC) and NIH guidelines. Animals were 
group housed in a standard 12:12 light-dark cycle. Mice were maintained on a C57BL/6 
background, or mixed C57BL/6 and 129P, or C57BL/6 and FVB backgrounds. Since 
phenotypes were specific to female mutant mice, animals of both sexes were used for initial 
analyses, and the sex of the animals used are clearly noted throughout the study. Pdx-Cre 
(B6.FVB-Tg(Pdx1-cre)6Tuv/Nci; RRID: IMSR_NCIMR:01XL5) mice were obtained from 
NCI Frederick Mouse Repository. MIP-GFP (B6.Cg-Tg(Ins1-EGFP)1Hara/J; RRID: 
IMSR_JAX:006864) mice were obtained from Jackson Laboratory. Adrb2f/f mice were a 
generous gift from Dr. Gerard Karsenty (Hinoi et al, 2008).  
 
Vessel Painting 
2-5 month old mice were anesthetized with 200 mg/kg avertin (intra-peritoneal injection) 
and perfused with 6µg/mL Alexa-488 conjugated wheat germ agglutinin (WGA; Life 
Technologies W11261). Pancreata were then dissected, incubated in 30% sucrose 
overnight, equilibrated in 1:1 Sucrose:OCT, then embedded in OCT and stored at -80°C. 
Floating 400µm cryo-sections were collected into 1X PBS. Sections were treated with 1% 
TritonX-100 for 1 hour at room temperature, blocked in 2% TritonX-100; 10% goat serum; 
0.02% sodium azide for 1 hour at room temperature, then incubated in primary antibody 
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(1:50 guinea pig anti-insulin) in antibody buffer (0.25% TritonX-100; 1% goat serum; 
0.02% sodium azide in 1X PBS) at room temperature for 24 hours. Sections were then 
washed and incubated in secondary antibody (anti-guinea pig Alexa-546 at 1:200; DAPI at 
1:1000) in antibody buffer at room temperature for 2 hours. Sections were cleared with 2:1 
benzyl benzoate:benzyl alcohol overnight at room temperature, mounted, and Z-stacks of 
1µm optical slices were taken using a Zeiss LSM 700 confocal microscope equipped with 
405, 488, 555, and 633 lasers. Maximum intensity projections through equal tissue depths 
were generated with FIJI. 
 
Other IHC 
50µm cryosections were taken from P6 mouse pancreata, then washed with PBS, 
permeabilized in 1% Triton X-100 in PBS, and blocked for 1 hour at room temperature 
using 5% goat serum (GS) in PBS + 0.1% Triton X-100. Sections were then incubated for 
2 nights at 4°C with either: rat anti-PECAM-1/CD-31 antibody (1:300), rabbit anti-TH 
antibody (1:500), rabbit anti-collagen IV (1:500), or chicken anti-laminin (1:200) in 
conjunction with guinea pig anti-insulin (1:300). Following PBS washes, sections were 
then incubated with anti-rat Alexa-546, anti-rabbit Alexa 488 or 647, anti-chicken 488 or 
647, and anti-guinea pig 488, 546, or 647 secondary antibodies (1:200; ThermoFisher). 
Sections were then washed in PBS and mounted in Fluoromount Aqueous Mounting 
Medium containing 100µg/mL DAPI. Z-stacks of 1µm optical slices were taken using a 
Zeiss LSM 700 confocal microscope equipped with 405, 488, 555, and 633 lasers. 
Maximum intensity projections were generated with FIJI, and quantification of 
sympathetic innervation density was done by calculating integrated TH fluorescence 
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density per unit area (FIJI) from multiple random images. Quantification of islet 
vasculature density was done by calculating integrated PECAM-1/CD-31 density per islet 




Young adult (2-4-month-old) mice were individually housed and fasted overnight (16 
hours) before being given a 2g/kg intraperitoneal (IP) glucose injection. Blood glucose 
levels were measured with a OneTouch Ultra 2 glucometer before glucose injection, and 2 
additional 2g/kg glucose injections were given at 30 minutes and 60 minutes after the first 
injection. Glucose levels were monitored over a 1.5-hour period. 
 
In vivo insulin tolerance 
Mice were individually housed overnight with ad libitum food and water before being 
given a 0.75U/kg IP insulin injection (Novolin-R). Blood glucose levels were measured 
with a OneTouch Ultra 2 glucometer before insulin injection, and every 15 minutes post-
injection over a 1-hour period. 
 
In vivo insulin secretion 
Mice were individually housed and fasted overnight (16 hours) before being given a 3g/kg 
IP glucose injection. Plasma insulin levels were measured with an Ultrasensitive Insulin 
92 
 
ELISA kit (Crystal Chem) before fasting (fed), the next morning before injection, and over 
a 1-hour period following injection. 
 
Mouse islet isolations 
Islets were isolated as previously described (Wollheim et al, 1990). Islets were isolated by 
collagenase distension through the bile duct (Collagenase P [Roche], 0.375-0.4mg/mL in 
HBSS) and digestion at 37°C. Digested pancreata were washed with HBSS + 0.1% BSA 
and subjected to discontinuous density gradient using histopaque (6:5 Histopaque 
1119:1077; Sigma-Aldrich). The islet layer (found at the interface) was collected and islets 
were handpicked under an inverted microscope for subsequent analysis.  
 
In vitro insulin secretion 
Isolated islets were cultured overnight in RPMI-1640 (5% FBS, 5U/L penicillin-
streptomycin). Islets were then were handpicked to be size and quantity matched, and 5-10 
islets/mouse were washed and pre-incubated for 1 hour in Krebs-Ringer HEPES buffer 
(KRHB) containing 2.8mM glucose. Islets were then incubated in 2.8mM or 16.7mM 
glucose, or 30mM KCl in KRHB for another 30 minutes. Supernatant fractions were 
removed, and islets lysed in acid-ethanol overnight and subsequently neutralized in Tris 
buffer (0.885M). Both cellular and supernatant fractions were subjected to insulin ELISA 




Transmission Electron Microscopy 
Pancreata were dissected from control and Adrb2 cKO mice that had either been fasted or 
given a 3mg/kg glucose challenge (15 minutes) and cut into ~1mm3 pieces then fixed in 
3% formaldehyde + 1.5% glutaraldehyde +2.5% sucrose in 0.1M NaCacodylate + 5mM 
CaCl2, pH 7.4 at room temperature for 1 hour. Pieces were then washed in 2.5% sucrose 
in 0.1M NaCacodylate + 5mM CaCl2 and post-fixed with 1% Palade’s OsO4 for 1 hour 
on ice, followed by incubation in Kellenberger’s uranyl acetate overnight at room 
temperature. Samples were then dehydrated with a graded alcohol series (50%, 75%, 95%, 
and 100% ethanol, then propylene oxide), embedded in Epon, and sectioned (~90nm) and 
collected onto EM grids. Grids were then imaged using an FEI Tecnai-12 TWIN 
transmission electron microscope operating at 100 kV and a SIS MegaView III wide-angle 
camera. A minimum of three -cells adjacent to a vessel per animal were quantified, and 
granules were considered docked if they were within 50nm of the apical plasma membrane. 
 
Calcium imaging 
Isolated islets were cultured overnight on laminin-coated (0.05-0.1mg/mL in HBSS + Ca2+ 
+ Mg2+) MatTek 35mm, No. 1.5 coverslip, 20mm glass diameter dishes in high glucose 
DMEM + L-glutamine supplemented with 10% fetal bovine serum (FBS), 5mL sodium 
pyruvate, 5U/L penicillin-streptomycin, and 2µl β-mercaptoethanol. Adhered islets were 
loaded with 4µM Fluo-4 AM (ThermoFisher) for 45 minutes in KRHB with 2.8mM 
glucose, then washed and incubated for 30 additional minutes in KRHB with 2.8mM 
glucose on a stage incubator (37°C and 5% CO2) for equilibration prior to imaging. Z-
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stacks representing 1µm optical slices of individual islets were collected every 15 seconds 
on a Zeiss AxioObserver Yokogawa CSU-X1 spinning disk confocal equipped with dual 
Evolve EMCCDs and 405, 488, 555, and 633 nm lasers. Zen Blue (2012) image collection 
software was used to maintain experimental parameters between individual experiments. 
Concentrated glucose was added by hand after 5 minutes and of background fluorescence 
collection (final concentration 20mM) and imaging continued for 10 minutes, before 
addition of concentrated KCl by hand (final concentration 30mM) to depolarize 
membranes. Imaging continued for 10 additional minutes, for a total of 25 minutes. No 
more than 30 seconds elapsed between imaging conditions.     
 
qRT-PCR 
RNA from either whole pancreata (P6) or isolated islets (adult) was isolated using 
TRIzol RNA extraction reagent phenol-chloroform extraction and ethanol precipitation. 
RNA from sorted cells was isolated using Direct-zol RNA Microprep (Zymo) kit. 1.5-2µg 
of total RNA was reverse-transcribed into cDNA with M-MLV Reverse Transcriptase 
(Promega). TaqMan assays (ThermoFisher) were used to quantitatively determine 
transcript levels of the adrenergic receptors, while Maxima SYBR Green/Rox Q-PCR 
Master Mix (ThermoFisher) reagents and primer sets (listed in Key Resources Table) were 
used to determine transcript levels for other genes. Both assays were performed in a 
StepOnePlus Real-Time PCR System (ThermoFisher). Fold change in transcript levels was 






Adrb2 i-cKO mice were injected subcutaneously with 180mg/kg tamoxifen (Sigma) in corn 




Beginning at five-six weeks of age, Adrb2 i-cKO mice were injected subcutaneously with 
180mg/kg tamoxifen (Sigma) in corn oil or corn oil alone, every day for five days. Four 
weeks after the last injection, vehicle- and tamoxifen-injected mice were subjected to 
metabolic assays. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Sample sizes were similar to those reported in previous publications (Borden et al., 2013; 
Houtz et al., 2016). For practical reasons, analyses of endocrine cell counts and 
quantifications from ultrastructural analyses (caveolae and fenestrae density, insulin 
granule density, insulin granule docking) were done in a semi-blinded manner, such that 
the investigator was aware of the genotypes prior to the experiment, but conducted the 
staining and data analyses without knowing the genotypes of each sample. All Student’s t-
tests were performed assuming Gaussian distribution, two-tailed, unpaired, and with a 
confidence interval of 95%, with the exception of fold change analyses (such as for qPCR), 
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which were done using a one sample t test. One-way ANOVA analyses with post hoc 
Tukey test or two-way ANOVA analyses with post hoc Bonferroni test were performed 
when more than 2 or 3 groups were compared, respectively. Statistical analyses were based 
on at least 3 independent experiments and described in the figure legends. All error bars 









CHAPTER 4: DEVELOPMENTAL 
ADRB2-MEDIATED VASCULAR 
REPRESSION IS REQUIRED FOR 











Developmental loss of β-cell Vegf-a and subsequent islet vasculature loss results in 
metabolic defects, in part due to insufficient exchange of hormones between β-cells and 
the bloodstream (Brissova et al., 2006; Lammert et al., 2003). In contrast, hyper-
vascularization of islets during development by overexpression of β-cell Vegf-a also results 
in glucose intolerance (Cai et al., 2012). However, loss of Vegf-a, and subsequent decrease 
in islet vasculature in adult islets has little effect on islet function (Reinert et al., 2013), 
suggesting a larger role for developmental Vegf-a signaling and islet vascular patterning 
in programming adult islet function. Islet endothelial cells also produce the vascular 
basement membrane, a specialized extracellular matrix consisting of collagen and laminin 
proteins that offer structural support, influence β-cell proliferation, and insulin gene 
transcription (Kaido et al., 2004; Nikolova et al., 2006; Nikolova et al., 2007). The 
signaling mechanisms controlling developmental vasculature patterning are not well 
understood, and there remains a need to fully delineate how islet vasculature is established, 
and how neonatal vascular patterning affects adult islet function. Here, we have shown that 
loss of Adrb2 in the pancreas results in increased intra-islet vasculature and functional 
defects in islet insulin secretion, in part due to an immature transcriptional profile. The 
question still remains, however, whether the developmental changes in islet vasculature are 
causal to the adult metabolic phenotypes. Previous studies have suggested that islet 
vascularization via Vegf-a is essential during development, but dispensable during 
adulthood (Reinert et al, 2013) to maintain glucose homeostasis. This is likely due to 
signaling through VEGFR-2 (KDR or Flk1), the primary Vegf-a receptor expressed in 
intra-islet endothelial cells (Brissova et al., 2006; Kim et al., 2011). Therefore, to assess if 
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the metabolic phenotypes seen in Adrb2 cKO mice were due to the increased islet 
vasculature, we used a blocking antibody against VEGFR-2 (Kim et al, 2011) to normalize 


















Blocking Vegf-a signaling ameliorates Adrb2 cKO morphological defects 
To investigate the underlying cause of the metabolic defects observed in Adrb2 
cKO mice, we hypothesized that the excess vasculature caused by Adrb2 deletion was the 
primary contributor to the metabolic defects. This hypothesis is built in part due to the 
published reports that vascular imbalance in islets results in glucose intolerance (Cai et al., 
2012; Reinert et al., 2013). To test this hypothesis, we used a vascular endothelial growth 
factor receptor 2 (VegfR-2/Flk1) blocking antibody to prevent the excess islet vasculature 
from occurring in Adrb2 cKO mice (Kim et al., 2011). Because we did not see increased 
Vegf-a transcription and islet hyper-vascularization in Adrb2 cKO mice before P2 (see 
Figures 2.4 and 2.6), we began injections with the blocking antibody at P0 so we could 
block the hyper-vascularization from occurring.  We injected mice at P0 and P3 and then 
either collected them at P6 or gave them a final injection and allowed them to grow to 
adulthood (Figure 4.1 A). Injections were stopped at P6 as islet vascularization is thought 
to be complete by that stage (Johansson et al., 2006a). Antibody-injected Adrb2 cKO mice 
survived to adulthood, had normal body weight, and did not exhibit any gross 
morphological abnormalities. Injection of the blocking antibody restored islet vasculature 
to control levels, as seen by IHC for PECAM1 (Figure 4.1 B-C). We additionally saw 
normalization of the basement membrane markers laminin and collagen IV (Figure 4.1 D). 
Because excess insulin production is a consequence of increased islet vasculature 
(Nikolova et al., 2006), and we demonstrated insulin production is increased in Adrb2 cKO 
hyper-vascularized islets, we assessed Ins2 transcript levels in antibody injected Adrb2 
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cKO pancreata. We found Ins2 transcription to be indistinguishable from control animals, 
and significantly reduced from control-injected Adrb2 cKO animals (Figure 4.1 E). This 
suggests the increased insulin in Adrb2 cKO islets is a consequence of increased 
vasculature.  
 
Blocking Vegf-a signaling ameliorates Adrb2 cKO functional defects 
In order to determine the contribution of the developmental morphological defects 
to the glucose intolerance observed in Adrb2 cKO animals, we assessed the metabolic 
profile in antibody injected Adrb2 cKO animals. Developmental blockade of islet hyper-
vascularization in Adrb2 cKO mice ameliorated the glucose intolerance seen in untreated 
Adrb2 cKO females to control levels (Figure 4.2 A-B). We additionally saw significant 
rescue of in vivo insulin secretion defects in antibody-injected Adrb2 cKO mice (Figure 
4.2 C). To be sure that restored glucose tolerance was due to restored islet insulin secretion, 
we assessed GSIS in vitro and saw full rescue of glucose-stimulated insulin secretion from 
antibody-injected Adrb2 cKO islets (Figure 4.2 D). Finally, we screened islets from Adrb2 
cKO females that had been treated with the VegfR2/Flk1 blocking antibody. Excitingly, 
we saw normalization of transcript levels of all GSIS genes as well as Neurod1 (Figure 4.3 
A). Together, these results suggest that Adrb2-dependent developmental vascular 
patterning through Vegf-a is required for acquisition of genes involved in GSIS, and whole 












Figure 4.1. Vegf pathway inactivation ameliorates developmental defects in Adrb2 
cKO mice. (A) Schematic for blocking activity of the Vegf-a receptor, Vegfr2, during 
development in Adrb2 cKO mice. (B) Neonatal hyper-vascularization and insulin 
immunoreactivity are rescued by blocking antibody injection. Scale bar, 25µm. (C) 
Quantification of vessel length (mm/mm2) shows significant rescue of hyper-
vascularization in Vegfr2 injected Adrb2 cKO mice. Means ± SEM from 3-4 female 
mice/condition, multiple islets per animal; one-way ANOVA, *p<0.05. (D) Laminin and 
Collagen IV immunoreactivity are normalized in Adrb2 cKO animals following blocking 
antibody injection. Scale bar 50µm. (E) Insulin transcript levels are normalized in female 
antibody injected Adrb2 cKO neonates (n=5-17 mice/condition; one-way ANOVA with 















Figure 4.2. Developmental Vegf pathway inactivation ameliorates adult functional 
defects in Adrb2 cKO mice.  (A) Glucose tolerance defects in Adrb2 cKO mice are 
significantly improved by blocking antibody injection during development. Means ± SEM 
from n= 5-10 mice/condition; one-way ANOVA with Tukey’s post-test *p<0.05, **p<0.01 
Adrb2 cKO + veh. compared to control, #p<0.05, ##p<0.01 Adrb2 cKO + veh. compared 
to Adrb2 cKO + AB. (B) Area under the curve (AUC) for glucose tolerance (one-way 
ANOVA with Tukey’s post-test ***p<0.001, n.s. not significant). (C) In vivo insulin 
secretion is significantly improved by blocking antibody injection. Means ± SEM for n= 
4-6 mice/condition; one-way ANOVAs with Tukey’s post-test *p<0.05 Adrb2 cKO + veh. 
compared to control, ##p<0.01 Adrb2 cKO + veh. compared to Adrb2 cKO + AB. (D) Islet 
insulin secretion is improved in Adrb2 cKO mice after developmental blockade of Vegf-a 
signaling. Means ± SEM from n= 3-5 mice/condition; one-sample t-tests and t-tests 












Figure 4.3. Developmental Vegf pathway inactivation ameliorates adult 
transcriptional defects in Adrb2 cKO islets. (A) Developmental blockage of Vegf 
signaling in Adrb2 cKO mice returns expression of islet GSIS genes to control levels. 












Pancreatic islets constitute less than 2% of the total pancreatic volume but receive 
disproportionality greater blood supply (Jansson and Hellerstrom, 1983), in part, because 
of the exquisite dependence of islet β-cells on a high and sustained oxygen supply for 
aerobic glycolysis. An intimate relationship between β-cells and intra-islet 
microvasculature is critical for multiple aspects of islet biology including β-cell mass, islet 
innervation, insulin secretion, and regenerative capacity of islets (Brissova et al., 2014; 
Brissova et al., 2006; Cai et al., 2012; Eberhard et al., 2010; Hogan and Hull, 2017; Reinert 
et al., 2014). This cross-talk between islet endothelial cells and β-cells is under precise 
regulation (Brissova et al., 2006; Cai et al., 2012), and a set-point of endothelial to β-cell 
ratios is critical for mature islet function (Hogan and Hull, 2017). In mice, hypo- or hyper-
vascularization of newly formed islets by β-cell-specific deletion (Brissova et al., 2006) or 
over-expression of Vegf-a (Cai et al., 2012), respectively, both elicit detrimental effects on 
β-cell mass and function, suggesting that Vegf-a levels in β-cells must be maintained within 
a narrow range. Surprisingly, inactivation of Vegf-a and subsequent islet hypo-
vascularization in adulthood did not perturb islet mass and insulin secretion and elicited 
only modest elevations in blood glucose (D’Hoker et al., 2013; Reinert et al., 2013). 
Together, these studies imply that the influence of the intra-islet vasculature and Vegf-a 
levels on islet morphology and function is predominately exerted during development. 
However, the factors modulating the precise control of β-cell Vegf-a expression, and the 
link between early islet vascular patterning and later metabolic functions, have remained 
poorly defined. Here, we reveal that Adrb2 in β-cells constitutes an endogenous brake to 
suppress Vegf-a production and curtail excessive endothelial cell expansion during the first 
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week of birth in mice, a period that is characterized by pronounced growth of intra-islet 
capillary network and endothelial cell proliferation (Johansson et al., 2006a). Our findings 
that normalization of islet vasculature in Adrb2 cKO mice additionally normalizes the 
transcriptional profile of these mice suggests that endothelial cells play a significant role 




























All procedures relating to animal care and treatment conformed to The Johns Hopkins 
University Animal Care and Use Committee (ACUC) and NIH guidelines. Animals were 
group housed in a standard 12:12 light-dark cycle. Mice were maintained on a C57BL/6 
background, or mixed C57BL/6 and 129P, or C57BL/6 and FVB backgrounds. Since 
phenotypes were specific to female mutant mice, animals of both sexes were used for initial 
analyses, and the sex of the animals used are clearly noted throughout the study. Adrb2f/f 
mice were a generous gift from Dr. Gerard Karsenty (Hinoi et al, 2008). Pdx-Cre (B6.FVB-
Tg(Pdx1-cre)6Tuv/Nci; RRID: IMSR_NCIMR:01XL5) mice were obtained from NCI 
Frederick Mouse Repository. 
 
VegfR2/Flk1 antibody injections 
Adrb2 cKO pups were injected with either 1µg of VegfR2/Flk1 blocking antibody (R&D 
AF644) or vehicle at P0 and P3, then either collected at P6 for RNA or 
immunohistochemistry, or given a third injection and allowed to mature. Pups given 3 
injections were subjected to glucose tolerance tests at 2 months of age, then collected for 






Young adult (2-4-month-old) mice were individually housed and fasted overnight (16 
hours) before being given a 2g/kg intraperitoneal (IP) glucose injection. Blood glucose 
levels were measured with a OneTouch Ultra 2 glucometer before glucose injection, and 2 
additional 2g/kg glucose injections were given at 30 minutes and 60 minutes after the first 
injection. Glucose levels were monitored over a 1.5-hour period. 
 
In vivo insulin tolerance 
Mice were individually housed overnight with ad libitum food and water before being 
given a 0.75U/kg IP insulin injection (Novolin-R). Blood glucose levels were measured 
with a OneTouch Ultra 2 glucometer before insulin injection, and every 15 minutes post-
injection over a 1-hour period. 
 
In vivo insulin secretion 
Mice were individually housed and fasted overnight (16 hours) before being given a 3g/kg 
IP glucose injection. Plasma insulin levels were measured with an Ultrasensitive Insulin 
ELISA kit (Crystal Chem) before fasting (fed), the next morning before injection, and over 
a 1-hour period following injection. 
 
Mouse islet isolations 
Islets were isolated as previously described (Wollheim et al, 1990). Islets were isolated by 
collagenase distension through the bile duct (Collagenase P [Roche], 0.375-0.4mg/mL in 
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HBSS) and digestion at 37°C. Digested pancreata were washed with HBSS + 0.1% BSA 
and subjected to discontinuous density gradient using histopaque (6:5 Histopaque 
1119:1077; Sigma-Aldrich). The islet layer (found at the interface) was collected and islets 
were handpicked under an inverted microscope for subsequent analysis.  
 
In vitro insulin secretion 
Isolated islets were cultured overnight in RPMI-1640 (5% FBS, 5U/L penicillin-
streptomycin). Islets were then were handpicked to be size and quantity matched, and 5-10 
islets/mouse were washed and pre-incubated for 1 hour in Krebs-Ringer HEPES buffer 
(KRHB) containing 2.8mM glucose. Islets were then incubated in 2.8mM or 16.7mM 
glucose, or 30mM KCl in KRHB for another 30 minutes. Supernatant fractions were 
removed, and islets lysed in acid-ethanol overnight and subsequently neutralized in Tris 
buffer (0.885M). Both cellular and supernatant fractions were subjected to insulin ELISA 




50µm cryosections were taken from P6 mouse pancreata, then washed with PBS, 
permeabilized in 1% Triton X-100 in PBS, and blocked for 1 hour at room temperature 
using 5% goat serum (GS) in PBS + 0.1% Triton X-100. Sections were then incubated for 
2 nights at 4°C with either: rat anti-PECAM-1/CD-31 antibody (1:300), rabbit anti-
collagen IV (1:500), or chicken anti-laminin (1:200) in conjunction with guinea pig anti-
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insulin (1:300). Following PBS washes, sections were then incubated with anti-rat Alexa-
546, anti-rabbit Alexa 488 or 647, anti-chicken 488 or 647, and anti-guinea pig 488, 546, 
or 647 secondary antibodies (1:200; ThermoFisher). Sections were then washed in PBS 
and mounted in Fluoromount Aqueous Mounting Medium containing 100µg/mL DAPI. Z-
stacks of 1µm optical slices were taken using a Zeiss LSM 700 confocal microscope 
equipped with 405, 488, 555, and 633 lasers. Maximum intensity projections were 
generated with FIJI, and quantification of sympathetic innervation density was done by 
calculating integrated TH fluorescence density per unit area (FIJI) from multiple random 
images. Quantification of islet vasculature density was done by calculating integrated 
PECAM-1/CD-31 density per islet (ROI set by insulin immunoreactivity) area (FIJI) from 
multiple random images.  
 
qRT-PCR 
RNA from either whole pancreata (P6) or isolated islets (adult) was isolated using 
TRIzol RNA extraction reagent phenol-chloroform extraction and ethanol precipitation. 
RNA from sorted cells was isolated using Direct-zol RNA Microprep (Zymo) kit. 1.5-2µg 
of total RNA was reverse-transcribed into cDNA with M-MLV Reverse Transcriptase 
(Promega). TaqMan assays (ThermoFisher) were used to quantitatively determine 
transcript levels of the adrenergic receptors, while Maxima SYBR Green/Rox Q-PCR 
Master Mix (ThermoFisher) reagents and primer sets (listed in Key Resources Table) were 
used to determine transcript levels for other genes. Both assays were performed in a 
StepOnePlus Real-Time PCR System (ThermoFisher). Fold change in transcript levels was 
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calculated using the 2(-ΔΔCt) method, and 18S was used as an endogenous control for 
normalization.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Sample sizes were similar to those reported in previous publications (Borden et al., 
2013; Houtz et al., 2016). For practical reasons, analyses of vessel length were done in a 
semi-blinded manner, such that the investigator was aware of the genotypes prior to the 
experiment, but conducted the staining and data analyses without knowing the genotypes 
of each sample. All Student’s t-tests were performed assuming Gaussian distribution, two-
tailed, unpaired, and with a confidence interval of 95%, with the exception of fold change 
analyses (such as for qPCR), which were done using a one sample t test. One-way ANOVA 
analyses with post hoc Tukey test or two-way ANOVA analyses with post hoc Bonferroni 
test were performed when more than 2 or 3 groups were compared, respectively. Statistical 
analyses were based on at least 3 independent experiments and described in the figure 










CHAPTER 5: TAMOXIFEN AFFECTS 
GLUCOSE TOLERANCE IN A SEX, 












The development of many cancer treatments stems from the clinical hypothesis that 
chemical compounds could be generated in such a way that they would be toxic only to the 
tumor without affecting the patient. This hypothesis depends on the identification and 
specific targeting of a factor present only on the tumorous tissue, and not present in any 
healthy host tissue. These ideas spurred a logical approach for chemotherapy design. As 
early as 1896, estrogen and estrogen receptor signaling was implicated in breast cancer 
development and progression after the discovery that surgical removal of the ovaries 
resulted in longer life expectancies for women with breast cancer (Jordan, 2001; Jordan, 
2006). From that point, estrogen-like chemicals (now called Selective Estrogen Receptor 
Modulators, or SERMs) became a widely researched drug category in an attempt to combat 
breast cancer. Unfortunately, the majority of drugs developed from this discovery had 
wide-spread and severe side-effects, and as such no SERMs were deemed acceptable for 
breast cancer treatment through the 1960s. During that same period of time, estrogen 
receptor modulators were also being developed in an attempt to generate emergency 
contraceptives. From this study, the drug Tamoxifen (TMX) was discovered. TMX itself 
is not highly effective at activating estrogen receptors, though it is metabolized by 
cytochrome P450 enzymes to 4-hydroxytamoxifen (4-HT), which binds both ER and ER 
with higher affinities than estrogen itself (Sasson and Notides, 1988). While TMX had 
absolutely no useful properties as a contraceptive (in humans) and was almost discarded, 
the connection was made that it may be useful as a breast cancer therapeutic. Many clinical 
trials began in the 1970’s and 80’s, and shortly thereafter TMX was declared effective at 
preventing breast cancer return. Since then, research on how and why TMX works has been 
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slow but steady. Currently, TMX is effective in both pre- and post- menopausal women 
with estrogen receptor (ER) positive breast cancer. Additionally, clinical trials are in 
process to determine the effectiveness of TMX at preventing breast cancer development in 
high-risk patients (such as those with ductal abnormalities).  
The term SERM was used to describe these compounds signaling properties as they 
act to both activate and repress estrogen receptor signaling depending on the species, tissue 
type, receptor specificity, and co-activators or co-repressors available (Jordan, 2001). This 
signaling complexity can be broken down into four core signaling decisions. The first 
decision TMX (or any SERM) must make is which estrogen receptor (ERα or ERβ) to bind 
to. This results in a conformational change in the receptor, which can influence the second 
decision: whether or not the receptor binds to a coactivator or corepressor. Depending on 
coactivator/repressor binding, the estrogen receptors can either homodimerize or 
hetereodimerize, the third decision. The final decision point is whether the homo- or hetero-
dimerized receptors activate or repress transcription. Transcriptional activation is either 
direct, via interaction with the DNA, or indirect, through interactions between the 
dimerized receptors and FOS and JUN. Repression is thought to be through direct contact 
with the DNA. Direct contact of dimerized receptors, both activating and repressing, occurs 
at estrogen response elements (EREs). While the exact mechanisms of TMX action are not 
well understood, these core ‘decisions’ are thought to underlie the species and tissue 
specific actions of TMX. For example, TMX was highly effective as a contraceptive in 
rodent models, but promoted ovulation (and increased pregnancy chances) in humans 
(Jordan, 2006). Furthermore, TMX is effective at preventing cancer recurrence in breast 
117 
 
tissue because it acts to repress growth, while it activates signaling in other tumor tissues, 
such as endometrial tumors.  
Considering the millions of individuals (mainly women) that have been treated with 
TMX, there is a very little clinical data available regarding the effects of tamoxifen 
treatment on body composition or energy homeostasis. In rodent models, TMX has been 
implicated in protecting against weight gain and adipose tissue accumulation (Wade and 
Heller 1993, Hesselbarth et al. 2015). TMX has also been found to prevent obesity, 
steatosis, and insulin resistance in high-fat diet (HFD) fed OVX mice (Guillaume et al. 
2017). Despite these findings, the full effects of TMX on metabolic homeostasis in wild-
type male and female mouse lines is unknown. A few studies investigating the effects of 
TMX have been done in only one sex (females, with the exception of one study on males 
in subcutaneous adipose tissue), and in different strains (CD1 and different C57BL6 
variants). However, it is likely that these effects of TMX are not only seen in one sex or in 
one genetic strain. These effects are likely dependent on a variety of factors, including 
TMX dose, and time allowed between TMX administration and phenotype testing (chase 
time). However, there are also potentially effects of background strain and delivery system 
(injection/injection type versus oral). To date, none of these effects of TMX have been 
characterized.    
Understanding the effects of TMX on metabolism is especially pertinent, as TMX 
is widely used to promote temporal genetic recombination in rodent systems using a 
modified Cre-Lox system. The Cre-Lox system involves Cre-recombinase and loxP sites, 
which were found in bacteriophage P1. Cre-recombinase, driven by a tissue-specific 
promoter, specifically ‘cuts’ DNA at specific sites, loxP sites, similar to restriction 
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enzymes. Depending on the orientation of these loxP sites, Cre-recombinase either excises 
the DNA between the sites or inverts it. By placing two loxP sites in an essential region of 
a gene of interest (generating a floxed allele) and combining this with a transgenic tissue-
specific promoter-driven Cre-recombinase, the gene of interest can be silenced in a tissue-
specific manner. This system is extremely powerful, but lacks temporal regulation, which 
is essential to differentiate adult versus developmental roles for genes, as well as avoiding 
embryonic lethality in certain systems. To avoid these confounds, the inducible Cre-lox 
system (CreER) was developed. This was done by fusing a modified estrogen receptor to 
Cre-recombinase. As previously mentioned, estrogen receptors are nuclear hormone 
receptors, which reside inactive in the cytosol, and only become active and transport to the 
nucleus upon ligand binding. The modified Cre-recombinase used in the CreER system is 
highly sensitive to the TMX metabolite 4-hydroxytamoxifen (4-OHT), and as such, 
delivery of TMX to a genetically modified organism results in spatiotemporally regulated 















Tamoxifen has long been used as a potent inducer of Cre activity in transgenic mice 
carrying Cre fused to a modified estrogen receptor (CreER). However, recent evidence 
suggests that tamoxifen causes significant physiological side effects, such as increased 
triglyceride and free fatty acid levels in male mice (Hesselbarth et al, 2015). Tamoxifen 
has also been shown to prevent weight gain and insulin resistance in ovariectomized female 
mice during high fat diet (Guillaume et al, 2017). Together, this suggests that in both male 
and female mice, tamoxifen alters whole body metabolism. To determine if tamoxifen 
affects glucose metabolism in mice, we performed a commonly used and recommended 
paradigm for tamoxifen-inducible deletion in three inbred strains: 129S1/SvImJ, BALB/cJ, 
and C57BL/6J. Following intraperitoneal (I.P.) injection of tamoxifen (100mg/kg/day for 
5 consecutive days), neither male nor female mice from any of the three strains showed 
significant changes in body weight (Figure 5.1 A-C).  
 
Glucose tolerance is improved by I.P. tamoxifen administration 
To determine the effects of tamoxifen on glucose metabolism, we performed 
glucose tolerance tests on males and females from all three strains following I.P. tamoxifen 
administration. While male 129S1/SvImJ mice did not display robust changes in glucose 
tolerance, we observed significantly improved glucose tolerance in tamoxifen treated 
129S1/SvImJ females, as well as BALB/cJ and C57BL/6J males and females (Figure 5.2 A-
I). These results highlight an important consequence of tamoxifen administration in 
improving glucose tolerance. Indeed, if a tamoxifen-induced knock-out showed no glucose 
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tolerance defects, then the effects of tamoxifen may have masked phenotypes if relevant 
tamoxifen-treated controls were not included. These results also highlight the importance 
of considering strain and sex while performing metabolic analyses. In agreement with this, 
we noted no changes in fed (ad libitum) blood glucose levels in response to tamoxifen in 
either 129S1/SvImJ or BALB/cJ male or female mice (Figure 5.3 A-B). However, both male 
and female C57BL/6J mice showed a significant but short-lived decrease in fed blood 
glucose levels in response to tamoxifen administration (Figure 5.3 C). Together, these 
results suggest that tamoxifen affects mouse strains with different propensities.  
 
Improved glucose tolerance persists following I.P. tamoxifen administration 
In order to determine the persistence of these effects, we extended the recovery 
period following tamoxifen administration to 21 days (3 weeks) after the final injection. 
Male 129S1/SvImJ mice did not develop improved glucose tolerance at 21 days post-
injection (Figure 5.4 A). Female 129S1/SvImJ and C57BL/6J mice displayed normal 
glucose tolerance by 21 days post-injection, while female BALB/cJ, male BALB/cJ, and 
male C57BL/6J mice retained their improved glucose tolerance (Figure 5.4 B-I). This 
suggests the glucose lowering effect that tamoxifen is having persists differently in a strain-
dependent manner, and weeks beyond the usually accepted ‘chase’ periods following 
tamoxifen administration in inducible Cre lines.  
 
Insulin sensitivity is unaffected by I.P. tamoxifen administration 
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Enhanced glucose tolerance can be caused by a variety of factors, including 
enhanced insulin secretion or sensitivity. To examine these possibilities, we tested whether 
I.P. tamoxifen administration increased insulin sensitivity in male C57BL/6J mice. We 
found no change in insulin tolerance two weeks following I.P. administration (Figure 5.5 
A). In contrast, we found a significant increase in glucose-stimulated insulin secretion 
(Figure 5.5 B). This suggests that increased insulin secretion is likely the cause of enhanced 
glucose tolerance following tamoxifen administration. Additionally, tamoxifen activity has 
been shown to be prolonged in pancreatic islets following tamoxifen treatment (Reinert et 
al, 2012), in agreement with the lasting nature of the effects we see. Furthermore, Estrogen 
Receptor signaling has been shown to promote glucose-stimulated insulin secretion, and 
tamoxifen is capable of binding to and activating endogenous estrogen receptors (Liu et al, 
2009; Wong et al, 2010).  
 
Oral tamoxifen delivery does not affect glucose tolerance 
Because tamoxifen metabolites have been shown to remain in circulation longer 
when delivered through I.P. injection versus oral administration (Wilson et al, 2014), we 
wanted to address whether the mechanism of tamoxifen delivery affected the glucose 
tolerance phenotypes. To test this, we placed mice on a tamoxifen or control diet for 10 
days (with a two-day break half-way through), allowed a 6-day recovery, and then 
examined glucose tolerance. Interestingly, we saw no changes in glucose tolerance 
following oral tamoxifen administration in male or female mice in any strain tested (Figure 
5.6 A-I). To ensure this was not due to a difference in dose, we calculated the amount of 
tamoxifen consumed based on food intake and found no significant difference in the total 
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amount of tamoxifen the animals received (approximately 500 mg/kg from injection 
compared to 440 ± 77 mg/kg for males and 432 ± 73 mg/kg for females (values are mean 
± SD for n=10 males and 11 females from all three strains)). This suggests that the method 








Figure 5.1. I.P. Tamoxifen administration does not affect weight in mice. (A) Male and 
female 129S1/SvImJ (B) BALB/cJ, or (C) C57BL/6J mice did not experience changes in 
weight gain in response to tamoxifen administration (blue bar).  Means ± SEM from n= 6 
male vehicle 129S1/SvImJ mice, 5 male TMX 129S1/SvImJ mice, 6 female vehicle 
129S1/SvImJ mice, 8 female TMX 129S1/SvImJ mice, 5 male BALB/cJ mice per condition, 
5 female vehicle BALB/cJ mice, 6 female TMX BALB/cJ mice, 6 male and female 













Figure 5.2. I.P. Tamoxifen administration improves glucose tolerance in mice one 
week after administration. (A) Male 129S1/SvImJ mice do not show changes in glucose 
tolerance in response to I.P. tamoxifen administration. Means ± SEM for n= 7 male 129S 
mice per condition. (B) TMX-injected female 129S1/SvImJ mice show significantly 
improved glucose tolerance. Means ± SEM for n=6 female 129S1/SvImJ mice per 
condition. (C) Area Under the Curve (AUC) for 129S1/SvImJ glucose tolerance. (D) Both 
male and (E) female BALB/cJ mice show significantly improved glucose tolerance 
following I.P. tamoxifen administration. Means ± SEM for n=5-7 BALB/cJ mice per sex 
per condition. (F) Area Under the Curve (AUC) for BALB/cJ glucose tolerance. (G) Both 
male and (H) female C57BL/6J mice show significantly improved glucose tolerance 
following I.P. tamoxifen administration. Means ± SEM for n= 6-9 C57BL/6J mice per sex 
per condition. (I) Area Under the Curve (AUC) for C57BL/6J glucose tolerance. *p<0.05, 






Figure 5.3. I.P. Tamoxifen administration affects blood glucose levels in a strain-
dependent manner. (A) Male and female 129S1/SvImJ and (B) BALB/CJ mice did not 
experience changes in fed blood glucose levels in response to tamoxifen administration 
(blue bar).  n= 6 male vehicle 129S1/SvImJ mice, 5 male TMX 129S1/SvImJ mice, 6 female 
vehicle 129S1/SvImJ mice, 8 female TMX 129S1/SvImJ mice, 5 male BALB/cJ mice per 
condition, 5 female vehicle BALB/cJ mice and 6 female TMX BALB/cJ mice. (C) Male 
and female C57BL/6J mice showed acutely lower fed blood glucose levels following 
tamoxifen injection. Levels normalized three weeks after the final injection in both sexes. 
n= 6 male and female C57BL/6J mice per condition. All data shown are means ± SEM. 











Figure 5.4. Improved glucose tolerance in I.P. tamoxifen injected mice persists three 
weeks after administration. (A) Male 129S1/SvImJ mice do not show changes in glucose 
tolerance in response to I.P. tamoxifen administration. Means ± SEM for n= 4 male 
129S1/SvImJ mice per condition. (B) Glucose tolerance in TMX-injected female 
129S1/SvImJ mice is normalized three weeks after tamoxifen injection. Means ± SEM for 
n=6 female 129S1/SvImJ mice per condition. (C) Area Under the Curve (AUC) for 
129S1/SvImJ glucose tolerance. (D) Both male and (E) female BALB/cJ mice retain 
significantly improved glucose tolerance three weeks post-I.P. tamoxifen administration. 
Means ± SEM for n=5-8 BALB/cJ mice per sex per condition. (F) Area Under the Curve 
(AUC) for BALB/cJ glucose tolerance. (G) Male, but not (H) female, C57BL/6J mice retain 
significantly improved glucose tolerance three weeks following I.P. tamoxifen 
administration. Means ± SEM for n=6-7 C57BL/6J mice per sex per condition. (I) Area 











Figure 5.5. Insulin sensitivity is unaffected by I.P. tamoxifen administration, but 
glucose-stimulated insulin secretion is increased. (A) Male C57BL/6J mice do not show 
changes in insulin sensitivity in response to I.P. tamoxifen administration. n= 6 male mice 
per condition. **p<0.01; one-sample t-tests. (B) Glucose-stimulated insulin secretion 
(GSIS) is improved following intraperitoneal tamoxifen administration in male C57BL/6J 




















Figure 5.6. Oral tamoxifen administration does not affect glucose tolerance. (A) Male 
and (B) female 129S1/SvImJ mice do not show changes in glucose tolerance in response to 
tamoxifen diet. Means ± SEM for n=3-5 129S1/SvImJ mice per sex per condition. (C) Area 
Under the Curve (AUC) for 129S1/SvImJ glucose tolerance. (D) Male and (E) female 
BALB/cJ mice do not show changes in glucose tolerance in response to tamoxifen diet. 
Means ± SEM for n=4-5 BALB/cJ mice per sex per condition. (F) Area Under the Curve 
(AUC) for BALB/cJ glucose tolerance. (G) Male and (H) female C57BL/6J mice do not 
show changes in glucose tolerance in response to tamoxifen diet. Means ± SEM for n=4-5 


















Here, we report that intraperitoneal (I.P.) tamoxifen administration to inbred strains 
has differential effects on glucose metabolism and insulin secretion. In three common 
strains, 129S1/SvImJ, BALB/cJ, and C57BL/6J, I.P. tamoxifen administration induced a 
significant and sustained improvement of glucose tolerance without affecting insulin 
sensitivity. The amplitude of the effects and the persistence of the effects were sex and 
strain dependent. Intriguingly, oral administration of tamoxifen did not cause these effects. 
These results highlight the need to adjust widely accepted tamoxifen administration 
protocols, such as by providing an extensive chase period following tamoxifen 
administration, testing different methods of administration, as well as including relevant 
tamoxifen-treated wild-type controls.  
The persistence of tamoxifen in the body appears to be highly age- and tissue-
dependent. These parameters are important to define in order to accurately utilize inducible 
Cre-loxP systems, especially in the context of temporally restricted results, such as lineage 
tracing. In young adult mice (2-3 months), tamoxifen and its metabolites are no longer 
detectable in brain tissue within 6-8 days of injection in a dose-dependent manner. Aged 
mice (older than 15 months), however, are unable to effectively clear tamoxifen from the 
same tissue (Valny et al, 2016). In pancreatic islets, however, the action of tamoxifen 
persists for much longer, on the order of weeks rather than days following administration 
in a dose-dependent manner (Reinert et al, 2012).  Our findings that glucose tolerance is 
enhanced following tamoxifen administration by I.P. injection highlights the importance 
of considering maximum induction efficiency as well of timing between injections and 
testing of metabolic parameters in mice. While the metabolic fates of tamoxifen following 
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I.P. injection versus oral administration is not known, it has been shown that 4-OHT, the 
tamoxifen metabolite most potent in terms of CreER activation, remains in plasma longer 
following I.P. injection compared to oral administration (Wilson et al, 2014). Together with 
our results showing that oral administration of tamoxifen does not impact glucose 
tolerance, this highlights the importance of considering and controlling for all aspects of 
tamoxifen administration in inducible systems.  
Although tamoxifen administration has been shown to protect against insulin 
resistance in ovariectomized females under high fat diet conditions (Guillaume et al, 2017), 
we found that under normal chow conditions, tamoxifen does not affect insulin sensitivity. 
We also found that this effect is, for the most part, not specific to female mice, with the 
exception of male 129S1/SvImJ mice. This is not all together surprising as it has been 
shown that estrogen directly affects insulin secretion from pancreatic islets (Lui et al, 
2009). Estrogen receptors in islets signal primarily through cytosolic pathways, in contrast 
to the canonical nuclear hormone receptor signaling pathways. Although tamoxifen is used 
because of its enhanced sensitivity for modified estrogen receptors, it is still capable of 
interacting with endogenous estrogen receptors. Combined, these results suggest that 
tamoxifen affects estrogen receptor signaling in multiple tissues, and that its effects may 









All procedures relating to animal care and treatment conformed to The Johns Hopkins 
University Animal Care and Use Committee (ACUC) and NIH guidelines. Animals were 
group housed in a standard 12:12 light-dark cycle. Animals of both sexes were used for all 
analyses and the sex of the animals used is clearly noted throughout. 129S1/SvImJ, 




Mice were individually housed and fasted overnight (16 hours) before being given a 2g/kg 
intraperitoneal (IP) glucose injection. Blood glucose levels were measured with a 
OneTouch Ultra 2 glucometer before glucose injection, and over a 2-hour period following 
injection.  
 
In vivo insulin secretion 
Mice were individually housed and fasted overnight (16 hours). Plasma insulin levels were 
measured with an Ultrasensitive Insulin ELISA kit (Crystal Chem) before injection and 






Beginning at 6 weeks of age, mice were injected intraperitoneally with 100 mg/kg 
tamoxifen (Sigma) in corn oil or corn oil alone, every day for 5 days. 1, 3, and 4 weeks 




At 5 weeks of age, mice were switched to either control diet or tamoxifen diet (Envigo 
TD.07570 and TD.130856) for five days. All mice were transferred to control diet for 2 
days, and then returned to either control or tamoxifen diet for another five days (total of 
ten days on diet over a twelve-day period). Because oral tamoxifen administration reduces 
food intake and body weight, mice were then given six days to recover (on standard chow) 
before glucose tolerance testing.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Sample sizes were similar to those reported in previous publications (Borden et al., 2013; 
Houtz et al., 2016). All Student’s t-tests were performed assuming Gaussian distribution, 
two-tailed, unpaired, and with a confidence interval of 95%, with the exception of insulin 
tolerance assays which were analyzed with one-sample t-tests. Statistical analyses were 
based on at least 3 independent experiments and described in the figure legends. All error 





















Developmental roles for adrenergic signaling 
Adrenergic signaling has been well-studied in the context of the fight-or-flight 
response, a series of acute, physiological responses to stress. However, the receptors and 
ligands that make up this complex signaling network are present throughout development 
in a variety of tissues, but their potential developmental roles have largely been ignored. 
This study uncovers a developmental role for β2-adrenergic signaling in organizing tissue-
tissue interactions during organogenesis (Figure 6). In the future it would be of interest to 
dissect the molecular pathway(s) through which this occurs, as well as to address whether 
other tissues similarly use adrenergic pathways during development.   
 
Sexual dimorphisms in islet biology 
Although it is well-established that males and females differ in many metabolic 
processes from food intake to fat storage, many studies in mice only address phenotypes in 
males. While the underlying reasons for this were not malicious (more females than males 
are needed as breeders to maintain mouse colonies, and hormone cycling can impact a 
variety of outputs), it has resulted in studies that are only relevant for half the population. 
The drastic female-specific phenotypes that we have described here highlight the need for 
including both sexes in mouse studies.  
How pancreatic islets, whose primary role is to control blood glucose homeostasis, 
develop and function differently in males versus females is unfortunately not often studied, 
even though islets are highly sexually dimorphic (recently reviewed Gannon et al, 2018). 
Furthermore, islets undergo massive changes in response to pregnancy, a female-specific 
requirement. This alone suggests that islet maintenance and function is, at least in part, 
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controlled by sex hormones. In agreement with this, intra-islet vasculature expands 
concurrently with β-cell expansion during pregnancy (Johansson et al, 2006b), supporting 
the thought that the vasculature of the pancreas should be more adaptable in females than 
in males. Our research suggests that this difference may be set up early in neonatal 
development. Additionally, islets from female donors have been suggested to be more 
amenable to transplantation than islets from male donors (Marchese et al, 2015). As failure 
to re-vascularize is one of the leading causes of islet graft failure, this again supports the 
hypothesis that female islets are more amenable to changes in vasculature status.  
 
Vasculature-β-cell interactions in diabetes 
Instructive roles of the vasculature in β-cell development have been previously 
described, though the mechanisms that control islet vascularization are largely unknown. 
Of the few studies available, even less has been elucidated regarding negative regulators, 
or pathways that put on the ‘brakes’ to restrict vasculature development. However, 
discovering these pathways is highly relevant considering excess intra-islet vasculature is 
known to cause metabolic defects. As mentioned previously, failure of islets to 
revascularize following transplantation is one of the leading causes of islet graft failure, 
our finding that β2-adrenergic signaling is a negative regulator of islet vasculature suggests 
that inhibition of β2-adrenergic signaling may improve islet transplant outcomes. 
Considering there are well established inhibitors of β-adrenergic signaling already 
approved for use in humans (commonly known as β-blockers), an exciting next step would 
be to see if our findings hold true in humans, and if the use of β-blockers could improve 
islet transplant outcomes.   
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Tamoxifen administration and use in mice 
Tamoxifen has been widely used to induce Cre activity in transgenic mice carrying 
a modified estrogen receptor (CreER). Tamoxifen is also widely known to act as an agonist 
and antagonist of estrogen receptor signaling, depending on a variety of factors, including 
tissue type and developmental stage. Yet despite this knowledge, tamoxifen-treated 
controls are rarely included in studies utilizing these CreER lines. This may be due to an 
effort to conserve the drug, or simply a consequence of available genotypes – because 
CreER; floxed animals should have no Cre activity, and therefore should be phenotypically 
wild-type, CreER; floxed animals are often mated to each other to increase the availability 
of CreER; floxed offspring for studies. This mating, however, results in very few, if any, 
Cre-negative animals to allow for littermate drug controls. However, our finding that 
tamoxifen lowers glucose during a glucose tolerance test across strains emphasizes the 








Figure 6. Adrb2 limits vascular growth in pancreatic islets during development to 
control islet function 
During islet development, β-cell-Adrb2 receptors suppress VEGF-A expression to limit 
excessive growth of intra-islet endothelial cells. Endothelial cells, in turn, are critical for 
precise regulation of insulin gene expression in neighboring β-cells, via producing vascular 
basement membrane proteins, and likely for transcriptional regulation of key components 
of insulin exocytosis. Loss of Adrb2 disrupts bi-directional signaling between islet β-cells 
and endothelial cells during development, resulting in islet hyper-vascularization, aberrant 
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